跳到正文
原文
Nature 综合主刊· Lukas Ramsauer·· 2 天前AI 评分60

癌细胞铁死亡触发PGE2产生介导cDC1功能障碍及肿瘤免疫逃逸

Ferroptosis in cancer cells triggers PGE 2 production for tumour immune escape

AI 导读

Nature论文发现,癌细胞发生铁死亡时,膜脂质过氧化物诱导Ca2+内流激活p38 MAPK信号,进而上调COX2表达并大量合成PGE2;PGE2经EP2/EP4受体抑制cDC1的CXCL9和IL-12分泌,阻碍CD8+ T细胞抗肿瘤免疫应答。基因敲除或药理学阻断PGE2-EP2/EP4信号可恢复cDC1功能、增强CD8+ TIL扩增,在小鼠黑色素瘤和结直肠癌模型中实现铁死亡肿瘤的免疫清除。

正文

Main

Uncontrolled lipid peroxidation is integral to ferroptosis5,15. Cancer cells are commonly protected from unrestrained lipid peroxidation and spontaneous ferroptotic cell death by molecular defence systems such as the system xc––glutathione (GSH)–glutathione peroxidase 4 (GPX4) pathway5,16, in which GPX4 is the key enzyme mediating lipid peroxide detoxification. Strategies to promote ferroptosis by blockade of ferroptosis defence systems, such as GPX4 inhibitors, have been considered promising approaches to achieve tumour elimination in patients with difficult-to-treat cancers8,9. Studies using preclinical mouse models have uncovered that effective tumour elimination by ferroptosis-inducing strategies requires anticancer immunity by DCs10 and tumour-infiltrating CD8+ T cells11,12,13. Yet recent findings have suggested that DC-driven anticancer CD8+ T cell immunity is suppressed in ferroptotic tumours8,9,10,17. Emerging evidence has implicated that the unrestrained generation of membrane lipid peroxides in ferroptotic cells can promote the production and release of molecules that may impact immune cell functions18. However, what causes the suppression of DC-mediated anticancer CD8+ T cell immunity in the context of tumour ferroptosis remains largely unclear.

Ferroptosis triggers PGE2 production in cancer cells

Potentially relevant immunoregulatory factors produced by ferroptotic cancer cells are oxylipins, bioactive lipids generated through peroxidation of polyunsaturated fatty acid-containing membrane lipids, a hallmark of ferroptosis15. To assess ferroptosis-induced oxylipin production and identify key factors, we profiled the oxylipin secretome of mouse BRAF(V600E) and NRAS(G12D) melanoma, 4T1 breast cancer and MC38 colorectal cancer cells following RSL3-induced ferroptosis. Across all these cancer cell lines, RSL3-treated (ferroptotic) cells displayed increased production of oxylipins compared with untreated (non-ferroptotic) controls (Fig. 1a). Of note, in all groups, the eicosanoid PGE2 was by far the most abundant oxylipin upregulated by ferroptosis induction (Fig. 1a). Similar to ferroptosis induction by RSL3 (which inhibits selenoproteins beyond GPX4), we observed strong PGE2 production after genetic ablation of the ferroptosis-protective enzyme GPX4, ferroptosis induction using the GPX4 inhibitor ML210 or erastin-mediated inactivation of system xc–-mediated cystine import (Extended Data Fig. 1a–f). Thus, ferroptosis may trigger the production of PGE2 in cancer cells, which is a notable finding given the important role of PGE2 for suppression of anticancer immunity19,20,21.

Fig. 1: Triggering of PGE2 production is characteristic of ferroptotic cancer cells and mediates cDC1 dysfunction.

a, Oxylipin profiles for the indicated cancer cell lines after RSL3 treatment. 4-HDHA, 4-hydroxydocosahexaenoic acid; 5,6-DHET, 5,6-dihydroxyeicosatrienoic acid; 6R-LXA4, 6R-lipoxin A4; 11-HETE, 11-hydroxyeicosatetraenoic acid; 15-oxoETE, 15-oxoeicosatetraenoic acid; DMSO, dimethyl sulfoxide; PDX, protectin DX; RvD1, resolvin D1; vs, versus. The vertical dotted line indicates a fold change (FC) (log2) of 0. b, PGE2 production by cancer cell lines after induction of ferroptosis, immunogenic cell death (ICD) or apoptosis. n = 4 samples for BRAF(V600E) melanoma, and n = 3 samples for NRAS(G12D) melanoma, 4T1 breast cancer and MC38 colorectal cancer. NS, not significant. c–f, Functional analyses of cDC1s exposed to dying cancer cell conditioned medium (CM). Experimental design (c). CXCL9 production by cDC1s; the plots show one cDC1 culture representative of n = 4 cultures (d). Quantification of CXCL9+ cDC1s, based on panel d; n = 4 samples (e). Analysis of cDC1s by RNA-seq (n = 4); the volcano plots show the effect of CM from ferroptotic (left) or apoptotic (right) BRAF(V600E) cells on activation-induced cDC1 genes (f). PE, phycoerythrin; RNA-seq, RNA sequencing; SSC-A, side scatter area. Data show mean ± s.e.m. of n = 3 biological replicates (a). In b, the centre line indicates the mean and the bounds show the minimum and maximum values. In e, the centre line indicates the median, the bounds extend from the 25th to the 75th percentile, and the whiskers correspond to he minimum and maximum values. P values are from one-way analysis of variance (ANOVA) with Tukey’s multiple-comparison test (two-sided; b,e). Differentially expressed genes were identified using a two-sided Wald test with Benjamini–Hochberg correction (f).

Source data

By contrast, stimulation of ultraviolet B (UVB)-induced apoptosis, doxorubicin-induced immunogenic cell death or necrocide 1 (NC1)-induced necrotic cell death failed to promote PGE2 production (Fig. 1b and Extended Data Fig. 1g). However, PGE2 production was induced in cells undergoing necroptosis (Extended Data Fig. 1h). These findings imply that PGE2 production is selectively induced by as yet unknown molecular events in ferroptotic cells and that these events, at least to some extent, may be shared with necroptotic cells.

Using liproxstatin-1 (Lip-1), we further validated that ferroptotic cancer cells depend on lipid peroxides to produce PGE2 (Extended Data Fig. 2a,b). This was not the case for key effectors of other cell death pathways, such as caspases or receptor-interacting serine–threonine-protein kinase 1 (RIPK1; Extended Data Fig. 2a,b). We extended our analyses to a broader panel of mouse and human cancer cells, including established cell lines, cells from spontaneous mouse cancer models and cells from patients with pancreatic cancer. In all these cells, RSL3-induced ferroptosis triggered markedly increased PGE2 production (Extended Data Fig. 2c–e). Together, these data suggest that ferroptosis promotes aberrant production of PGE2 in mouse and human cancer cells, prompting us to investigate the underlying molecular mechanisms and consequences for anticancer immunity.

PGE2 released by ferroptotic cancer cells causes cDC1 dysfunction

Effective anticancer immunity often depends on cDC1s22,23, which fulfil essential roles in the priming of anticancer CD8+ T cell responses24,25 and effector differentiation and expansion of CD8+ tumour-infiltrating T lymphocytes (TILs)26,27. These cDC1 functions are impacted by immunoregulatory factors derived from dying cancer cells22,23,28; however, how mediators released by ferroptotic cancer cells impact cDC1s and their functions is not known.

To address this issue, we generated cDC1s from bone marrow cells, exposed them to conditioned medium from RSL3-induced, ferroptotic BRAF(V600E) melanoma cells and assessed their functional properties after activation with polyinosinic–polycytidylic acid (poly(I:C); Fig. 1c). The conditioned medium from ferroptotic BRAF(V600E) cells strongly compromised the capacity of cDC1s to produce CXCL9 (Fig. 1d,e and Extended Data Fig. 3a), a chemokine required for cDC1-mediated orchestration of CD8+ TIL responses26,29. Similar results were observed for cDC1 production of the T cell stimulatory cytokine interleukin-12 (IL-12)30 (Extended Data Fig. 3b,c). By contrast, no impairment was observed for cDC1s exposed to conditioned medium from cancer cells undergoing apoptosis or doxorubicin-induced immunogenic cell death (Fig. 1d,e and Extended Data Fig. 3b,c). Impaired CXCL9 production was similarly observed for splenic cDC1s treated with conditioned medium from ferroptotic BRAF(V600E) cells (Extended Data Fig. 3d). These results suggest that factors released by ferroptotic cancer cells disable cDC1s from producing molecules required to promote anticancer CD8+ T cell immunity.

cDC1 functions are controlled by transcriptional programming31,32. We therefore subjected cDC1s activated by poly(I:C) following exposure to ferroptotic or apoptotic BRAF(V600E) cell conditioned medium to transcriptional profiling by RNA sequencing. We found that ferroptotic, but not apoptotic, cancer cell-derived factors induced prominent transcriptional changes in cDC1s (Fig. 1f), including impaired expression of genes encoding stimulatory cytokines (including Ifnb and Ifnl2), T cell-recruiting chemokines (Cxcl9 and Ccl4) and integrins important for T cell activation (Itgal; Fig. 1f). We also confirmed the inhibitory effect on cDC1 cytokine and chemokine production at the protein level (Extended Data Fig. 3e). Of note, we did not detect a defect in upregulation of MHC or costimulatory molecules (Fig. 1f and Supplementary Table 1), implying that ferroptotic cancer cell-derived factors do not prevent cDC1 activation. Of note, many of the genes impaired in cDC1s following exposure to ferroptotic cancer cell-derived factors were shared with a core gene set of PGE2-mediated cDC1 dysfunction (Extended Data Fig. 3f,g and Supplementary Table 1), although genes beyond this set were also impaired. Consistently, gene set enrichment analyses revealed a prominent impairment of PGE2-regulated functional cDC1 genes (Extended Data Fig. 3h), whereas genes associated with migration or antigen processing (that is, molecular programs not regulated by PGE2 signalling in cDC1s19), remained unaffected (Extended Data Fig. 3h). Together, these data suggest that ferroptotic cancer cells promote cDC1 dysfunction and that this is mediated by PGE2.

Ca2+-dependent p38 MAPK signalling drives PGE2 production

Similar to cancer cells, ferroptosis induction caused aberrant PGE2 production in Pfa1 cells (Extended Data Fig. 4a), an established mouse embryonic fibroblast model often used to study the molecular underpinnings of ferroptosis33. This was linked to markedly increased transcript and protein expression of the key PGE2-producing enzyme COX2 (encoded by Ptgs2; Fig. 2a and Extended Data Fig. 4b–d). Lip-1 treatment rescued this effect (Fig. 2a), whereas stimulation of lipid peroxidation by cumene hydroperoxide promoted both Ptgs2 expression and increased PGE2 production in Pfa1 cells (Extended Data Fig. 4e,f). Together, these results point towards a requirement of membrane lipid peroxide generation for PGE2 production through transcriptional regulation of COX2. Using COX inhibitors, we also confirmed that COX activity was required for PGE2 production by ferroptotic Pfa1 cells (Fig. 2b), but dispensable for execution of ferroptotic cell death (Fig. 2c).

Fig. 2: PGE2 production by ferroptotic cells is uncoupled from cell death and mediated through Ca2+-induced p38 MAPK signalling.

a–r, Molecular analyses of RSL3-induced, ferroptotic Pfa1 cells. Transcript expression of COX–PGE2 pathway enzymes; n = 3 samples (a). mPtges1, microsomal Ptges1. Effect of CXB (1, 10 or 100 nM) or acetylsalicylic acid (ASA) (1, 10 or 100 µM) on PGE2 production (b) and cell viability (c); n = 3 samples. Microscopy analysis of Ca2+ influx (fluo-8-AM) after 8 h (d). Scale bars, 10 µm. The dashed lines indicate cell borders. Quantification of Ca2+ influx, based on panel d; n = 45 cells for DMSO control and n = 60 cells for RSL3 (e). Time-resolved live cell imaging of lipid peroxidation (BODIPY C11), Ca2+ influx (CalBryte 630-AM) and cell death (Sytox blue); n = 4 samples (f). Effect of PEG treatment; n = 3 samples (g–j): experimental design (g); quantification of Ptgs2 mRNA (h) and COX2 protein (i) expression after 8 h; and measurement of PGE2 production (j). Effect of EGTA on PGE2 production; n = 3 samples (k). Representative western blot of p-p38 protein expression after 8 h (l). Quantification of p-p38 and total p38 expression, based on panel l; n = 3 samples (m). Effect of SB203580-mediated p38 MAPK inhibition on COX2 expression after 8 h (n), PGE2 production (o) and cell viability (p); n = 3 samples. Effect of Lip-1 on cell viability (q). Oxylipin profiles of cells treated as indicated; n = 3 samples (r). DHETE, dihydroxyeicosatetraenoic acid; DiHOME, dihydroxyoctadecenoic acid; EET, epoxyeicosatrienoic acid; EpOME, epoxy octadecenoic acid; HETrE, hydroxyeicosatrienoic acid; HODE, hydroxyoctadecadienoic acid; LOOH, lipid hydroperoxide; TXB2, thromboxane B2. s, Schematic illustrating the mechanistic underpinnings of PGE2 production in ferroptotic cancer cells. Data depict mean ± s.e.m. (b,c,p,q). Data are depicted as boxplots (h–k,m–o). Plots show data for one sample of n = 6 samples from two independent experiments (d,f,l). In h–k,m–o, the centre line indicates the mean and the bounds show the minimum and maximum values. P values are from one-way ANOVA with Tukey’s multiple-comparison test (b,c,h–k,m–q) or unpaired Student’s t-tests (e). NS (P ≥ 0.05).

Source data

A key event caused by lipid peroxides in ferroptotic cells is the influx of extracellular Ca2+ (ref. 5), which constitutes an early event in pro-ferroptotic cells before the onset of cell death. Consistently, microscopy imaging revealed high intracellular Ca2+ levels in Pfa1 cells early after RSL3-mediated ferroptosis induction (Fig. 2d,e), which was similarly observed for multiple mouse cancer cells (Extended Data Fig. 4g,h). Time-resolved live cell imaging of ferroptotic Pfa1 cells confirmed that Ca2+ influx followed peroxide accumulation, but occurred before the cell death-associated loss of plasma membrane integrity (Fig. 2f). Of note, preventing Ca2+ influx through polyethylene glycol (PEG)-mediated blockade of membrane permeabilization-enabled osmotic molecule exchange5,34,35 (Fig. 2g and Extended Data Fig. 4i,j) abrogated the upregulation of Ptgs2 mRNA (Fig. 2h) and COX2 protein expression (Fig. 2i) in ferroptotic Pfa1 cells, resulting in a loss of PGE2 production (Fig. 2j). We also validated that lipid peroxide generation was only minimally affected by PEG treatment (Extended Data Fig. 4k,l) and that ferroptotic cells become permeable to other small extracellular molecules5, including sodium ions (Na+; Extended Data Fig. 4m–p).

Gain-of-function experiments using ionomycin, which selectively transport extracellular Ca2+ into cells, revealed that Ca2+ influx alone was sufficient to promote COX2 upregulation and PGE2 production across Pfa1, BRAF(V600E) melanoma and MC38 colorectal cancer cells (Extended Data Fig. 4q,r). Thus, although small molecules beyond Ca2+ enter ferroptotic cells, they probably do not contribute substantially to the activation of COX-mediated PGE2 production. Consistently, blockade of Ca2+ influx using the Ca2+ chelator EGTA confirmed the relevance of Ca2+ signalling for PGE2 production in ferroptotic cells (Fig. 2k and Extended Data Fig. 4s,t).

Ca2+ influx can regulate gene expression via p38 MAPK signalling, which requires p38 MAPK activatory phosphorylation (p-p38). Consistently, ferroptotic Pfa1 cells displayed a prominent increase in p-p38 levels (Fig. 2l,m), which was abolished by PEG treatment (Fig. 2l,m). Moreover, treatment with the selective p38 MAPK inhibitor SB203580 abrogated the upregulation of COX2 expression and PGE2 production in ferroptotic Pfa1 cells (Fig. 2n,o), demonstrating the relevance of p38 MAPK signalling for PGE2 production. Of note, the later execution of cell death remained unaffected by p38 MAPK inhibition (Fig. 2p) or blockade of Ca2+ influx (Extended Data Fig. 5a). These results suggest that Ca2+-induced p38 MAPK signalling is not required for ferroptotic cell death. We also confirmed that SB203580 did not induce cell death in non-ferroptotic cells (Extended Data Fig. 5a), and that the death of SB203580-treated ferroptotic Pfa1 cells was rescued by Lip-1 (Fig. 2q).

Oxylipin profiling revealed a selective requirement of p38 MAPK signalling for production of PGE2 and other COX-derived eicosanoids in ferroptotic Pfa1 cells (Fig. 2r), whereas other oxylipins remained largely unaffected. Similar to Pfa1 cells, PEG-mediated inhibition of Ca2+ influx or inhibition of p38 MAPK abolished PGE2 production in ferroptotic cancer cells (Extended Data Fig. 5b–e), demonstrating the relevance of Ca2+-mediated p38 MAPK pathway activation for PGE2 production also in ferroptotic cancer cells. We also confirmed that, in cancer cells, this mechanistic axis is already active in the early phase after ferroptosis induction (Extended Data Fig. 5f–r) and that p38 MAPK signalling is dispensable for the propagation of ferroptotic cell death (Extended Data Fig. 5s–v). Experiments with cells deficient in p38α (the p38 MAPK isoform commonly expressed in cancer cells) further validated that p38 MAPK signalling is required for PGE2 production by ferroptotic cancer cells (Extended Data Fig. 5w,x), but not their cell death execution (Extended Data Fig. 5y). We conclude that Ca2+-mediated activation of p38 MAPK signalling triggers PGE2 production by ferroptotic cells and that this mechanism is not required for ferroptosis-dependent cancer cell death (Fig. 2s). This molecular uncoupling enables to selectively interfere with p38 MAPK pathway activity to impair PGE2 production by ferroptotic cancer cells while preserving ferroptosis-mediated cancer cell elimination.

PGE2–EP2/EP4 signalling mediates cDC1 inhibition

To test whether ferroptotic cancer cells depend on PGE2 to promote cDC1 dysfunction, we induced ferroptosis in COX-deficient Ptgs1/Ptgs2−/− BRAF(V600E) melanoma cells, which cannot produce PGE2 (Extended Data Fig. 6a–c). We then exposed cDC1s to conditioned medium from ferroptotic Ptgs1/Ptgs2−/− or control BRAF(V600E) cells, activated them by poly(I:C) and compared their gene expression profile by RNA sequencing (Fig. 3a). We also included cDC1s exposed to conditioned medium from apoptotic BRAF(V600E) cells, to test possible effects of dying cancer cell-derived factors unrelated to ferroptosis. We observed that PGE2 deficiency in ferroptotic BRAF(V600E) cells prevented cDC1 reprogramming (Fig. 3b) and, consequently, rescued the expression of functional cDC1 genes (for example, Irf8, Ifnl2 and Cxcl9; Fig. 3c). This regain of gene expression was similarly observed in a more detailed analysis of the core functional cDC1 genes selectively suppressed by factors from ferroptotic, but not apoptotic, BRAF(V600E) cells (Fig. 3d).

Fig. 3: Interference with PGE2 signalling rescues cDC1s from ferroptotic cancer cell-induced dysfunction and permits cDC1-mediated CD8+ T cell expansion.

a, Experimental design for panels b–d. b, Principal component (PC) analysis of differentially expressed genes in cDC1s treated as indicated. c, Effect of COX deficiency in ferroptotic BRAF(V600E) cells on gene expression of poly(I:C)-activated cDC1. d, Heatmap showing the expression of core functional cDC1 genes. e–g, Effect of EP2/EP4 deficiency on ferroptotic cancer cell-induced cDC1 dysfunction: heatmap showing the expression of core functional genes in WT or ItgaxcrePtger2−/−Ptger4fl/fl cDC1s treated as indicated (e); flow cytometry plots showing CXCL9 expression, with one of n = 5 samples (f); and quantification of CXCL9+ cDC1s, based on panel f (g; n = 6 samples for WT, and n = 5 samples for ItgaxcrePtger2−/−Ptger4fl/fl). Data show mean ± s.e.m. h,i, Effect of ferroptotic cancer cell-derived CM on cDC1-induced CD8+ T cell expansion: experimental design (h), and quantification of CD8+ T cell expansion (i; n = 3 samples). In i, the centre line indicates the mean and the bounds show the minimum and maximum values. Differentially expressed genes were identified by two-sided Wald test with multiple testing using the Benjamini–Hochberg method (c). P values are from one-way ANOVA with Tukey’s multiple-comparison test (g,i). NS (P ≥ 0.05).

Source data

The inhibitory effect of PGE2 on immune cells36, including cDC1s19, is mediated by signalling through the PGE2 receptors EP2 (encoded by Ptger2) and EP4 (encoded by Ptger4). We therefore extended our RNA sequencing analyses to EP2/EP4-deficient cDC1s from ItgaxcrePtger2−/−Ptger4fl/fl mice19,26. Whereas conditioned medium from PGE2-producing ferroptotic control BRAF(V600E) cells compromised the upregulation of activation induced genes in (EP2/EP4-proficient) wildtype (WT) cDC1s, this defect was fully rescued in EP2/EP4-deficient cDC1s (Fig. 3e and Supplementary Table 2). This result demonstrates the relevance of PGE2–EP2/EP4 signalling for ferroptotic cancer cell-mediated impairment of cDC1 functions. In separate experiments, we further validated that CXCL9 and IL-12 production is rescued in both EP2/EP4-deficient cDC1s treated with conditioned medium from ferroptotic BRAF(V600E) cells and cDC1s treated with conditioned medium from (PGE2-deficient) ferroptotic Ptgs1/Ptgs2−/− (BRAF(V600E)) cells (Fig. 3f,g and Extended Data Fig. 6d,e). Using CXCL9 as a functional marker, we also confirmed that PGE2 was similarly required for ferroptotic cancer cell-mediated inhibition of cDC1s activated by stimuli reported to promote cDC1 activation in tumours (Extended Data Fig. 6f,g). In a T cell stimulation assay, we further probed the ability of cDC1s to stimulate CD8+ T cell expansion. This function was similarly rescued in cDC1s exposed to conditioned medium from PGE2-deficient ferroptotic BRAF(V600E) cells (Fig. 3h,i). Using celecoxib (CXB)-mediated blockade of PGE2 production, we also confirmed that other ferroptotic cancer cells depend on PGE2 to inhibit cDC1 function, as determined by CXCL9 staining (Extended Data Fig. 6h,i). Together, these findings suggest that PGE2–EP2/EP4 signalling mediates the impairment of cDC1 functions caused by ferroptotic cancer cells. Moreover, EP2/EP4 deficiency rescues cDC1s from ferroptotic cancer cell-mediated inhibition.

PGE2 from ferroptotic cancer cells impairs anticancer immunity

Our results raised the question whether cDC1s can mount effective CD8+ T cell responses against ferroptotic cancer cells when protected from inhibitory PGE2 signalling. To address this issue, we adoptively transferred CD8+ OT-I T cells, which express a transgenic T cell receptor (TCR) specific for the model antigen ovalbumin (OVA), into WT mice subsequently transplanted with ferroptotic, OVA-expressing control or Ptgs1/Ptgs2−/− BRAF(V600E) cells (Extended Data Fig. 7a). To determine the relevance of EP2/EP4-mediated PGE2 signalling in cDC1, we further included Clec9acrePtger2−/−Ptger4fl/fl mice, which lack EP2 and EP4 in CLEC9A-expressing cDC1. Analyses of OT-I T cell expansion in lymphoid tissues revealed that ferroptotic cancer cell-derived PGE2 impairs the productive generation of anticancer CD8+ T cell responses through PGE2-mediated inhibition of cDC1 functions (Extended Data Fig. 7b–e). Moreover, OT-I T cell expansion was lost in cDC1-deficient Batf3−/− mice challenged with ferroptotic BRAF(V600E)–OVA cells (Extended Data Fig. 7f), confirming the functional relevance of cDC1s for generation of anticancer CD8+ T cell responses.

EP2/EP4 deficiency in cDC1s restores anticancer T cell immunity

To determine whether ferroptotic tumours depend on PGE2 production to restrict cDC1-mediated anticancer CD8+ TIL responses and escape immune control, we analysed the growth of (ferroptotic) Gpx4−/− or (non-ferroptotic) WT MC38 cells transplanted into WT and Clec9acrePtger2−/−Ptger4fl/fl mice (Fig. 4a). By microscopy-based analysis of the ferroptosis marker 4-hydroxynonenal (4-HNE) and COX2 protein, we confirmed cancer cell ferroptosis leading to enhanced COX pathway activity in Gpx4−/−, but not WT, MC38 tumours (Extended Data Fig. 8). In WT mice, tumours formed by Gpx4−/− MC38 cells exhibited progressive tumour growth, which was only minimally slower than WT MC38 cells (Fig. 4b and Extended Data Fig. 9a). These data are consistent with inefficient control of ferroptotic cancers in immunocompetent mice. By contrast, Clec9acrePtger2−/−Ptger4fl/fl mice exhibited improved tumour immune control and fully rejected Gpx4−/− MC38 tumours (Fig. 4b and Extended Data Fig. 9a). By contrast, WT MC38 tumours displayed reduced growth but failed to be eliminated in Clec9acrePtger2−/−Ptger4fl/fl mice (Fig. 4b and Extended Data Fig. 9a). Of note, this pattern was similarly observed for Cd4crePtger2−/−Ptger4fl/fl mice in which T cells lack EP2/EP4 expression (Extended Data Fig. 9b), implying that ferroptotic tumours, in parallel to inhibiting cDC1, depend on PGE2-mediated inhibition of T cells to escape anticancer immunity.

Fig. 4: Preventing PGE2–EP2/EP4 signalling restores cDC1-induced anticancer CD8+ T cell responses and achieves immune control of ferroptotic tumours.

a, Experimental design for panels b–i. s.c., subcutaneous. b, Tumour growth profiles of WT or Gpx4−/− MC38 cells transplanted into WT (n = 12) or Clec9acrePtger2–/–Ptger4fl/fl (n = 9) mice. c, Quantification of intratumoural CXCL9+ cDC1s at day 6 after tumour transplantation (n = 7 for WT MC38 into WT; n = 8 for Gpx4−/− MC38 into WT; n = 7 for WT MC38 into Clec9acrePtger2−/−Ptger4fl/fl; and n = 8 for Gpx4−/− MC38 into Clec9acrePtger2−/−Ptger4fl/fl). d–l, Functional analysis of CD8+ TILs at day 8 after tumour transplantation (n = 7 for WT MC38 into WT, Gpx4−/− MC38 into WT, and WT MC38 into Clec9acrePtger2−/−Ptger4fl/fl; and n = 8 for Gpx4−/− MC38 into Clec9acrePtger2−/−Ptger4fl/fl). CD8+TCRβ+ TIL frequencies (d). Quantification of total CD8+ TILs (e). Frequencies of TIM3+CD8+ effector TILs (f). GZMB expression in TIM3+CD8+ TILs (g). Quantification of GZMB+TIM3+ TILs based on panel g (h). Ki-67 expression in TIM-3+CD8+ TILs (i). j–l, WT or Gpx4−/− MC38 cells were transplanted into WT mice treated or not with CXB: tumour growth profiles (j; n = 10), and quantification of CD8+ TILs at day 8 after tumour transplantation (k; n = 5). WT mice were transplanted with BRAF(V600E) cells and treated with CXB or IKE from day 5 after tumour transplantation (l). Tumour growth was analysed relative to baseline tumour size at day 5 (n = 20 for untreated; n = 20 for +IKE; n = 22 for +CXB; and n = 20 for +IKE and CXB). Data were pooled from two independent experiments (b,c,e,f,h–l). Plots show data for one sample representative of n = 7 samples (d,g). Data are presented as mean ± s.e.m. (b,j,l). In c,e,f,h,i,k, the centre line indicates the median, the bounds extend from the 25th to the 75th percentile, and the whiskers correspond to he minimum and maximum values. P values are from two-way ANOVA with Bonferroni’s correction for multiple testing (b,j,l) or one-way ANOVA with Tukey’s multiple-comparison test (c,e,f,h,i,k).

Source data

We also genetically ablated p38α in Gpx4−/− MC38 cells, which disabled ferroptosis-induced PGE2 production (Extended Data Fig. 9c) and resulted in enhanced tumour growth control in WT mice (Extended Data Fig. 9d), consistent with the idea that p38 MAPK-induced PGE2 production by ferroptotic tumours promotes immune escape.

Of note, the efficient elimination of Gpx4−/− MC38 tumours in Clec9acrePtger2−/−Ptger4fl/fl mice was linked to markedly increased intratumoural numbers of CXCL9-producing cDC1s (Fig. 4c), indicating their enhanced anticancer activity. By contrast, the numbers of CXCL9-producing cDC1s remained low in Gpx4−/− MC38 tumours in WT mice, and in WT MC38 tumours in both WT and Clec9acrePtger2−/−Ptger4fl/fl mice (Fig. 4c). Confocal immunofluorescence microscopy further revealed a prominent increase of interactive clusters between cDC1s and CD8+ TILs in Gpx4−/− MC38 tumours in Clec9acrePtger2−/−Ptger4fl/fl mice (Extended Data Fig. 9e,f), pointing towards more productive cDC1-mediated instruction of anticancer CD8+ TIL responses19,26. Consistently, CD8+ TILs displayed substantially enhanced expansion in Gpx4−/− MC38 tumours in Clec9acrePtger2−/−Ptger4fl/fl mice compared with all other groups (Fig. 4d,e).

cDC1s fulfil an essential role in anticancer immunity by driving the expansion and effector differentiation of TCF1+CD8+ TILs (often referred to as ‘stem-like’ T cells) into TIM3+(TCF1−)CD8+ TILs with cytotoxic effector functions26. In many tumours, this process is critical for protective anticancer immunity37,38,39,40. The CD8+ TILs selectively accumulating in Gpx4−/− MC38 tumours in Clec9acrePtger2−/−Ptger4fl/fl mice predominantly encompassed TIM3+(TCF1−)CD8+ TILs (Fig. 4f and Extended Data Fig. 10a) with high PD-1 and CXCR6 expression (Extended Data Fig. 10a), indicating more productive effector differentiation20,40. Consistently, TIM3+ TILs in Gpx4−/− MC38 tumours in Clec9acrePtger2−/−Ptger4fl/fl mice showed markedly increased frequencies of cells expressing the cytotoxic effector molecule granzyme B (GZMB) compared with all other groups (Fig. 4g,h). We also confirmed that the numbers of stem-like TCF1+ TILs were comparable across all groups (Extended Data Fig. 10b), consistent with their unaffected tumour infiltration.

Of note, the few TIM3+CD8+ TILs detectable in Gpx4−/− MC38 tumours in WT mice, similar to Gpx4−/− MC38 tumours in Clec9acrePtger2−/−Ptger4fl/fl mice, displayed high expression of the proliferation marker Ki-67 (Fig. 4i and Extended Data Fig. 10c). This result indicates that CD8+ TILs, at least to some degree, mount proliferative responses also in ferroptotic tumours in the presence of intact PGE2 signalling on cDC1s. However, profiling of CD8+ TILs at later stages demonstrated that, in Gpx4−/− tumours in WT mice, these responses are not sustained over time, both in terms of Ki-67 expression, GZMB expression and CD8+ TIL expansion (Extended Data Fig. 10d–f). By contrast, CD8+ TIL responses in Clec9acrePtger2−/−Ptger4fl/fl mice in Gpx4−/− MC38 tumours further increased over time (Extended Data Fig. 10d–f). Thus, only Clec9acrePtger2−/−Ptger4fl/fl mice, but not WT mice, can mount protective CD8+ T cell immunity against ferroptotic tumours. By antibody-mediated CD8+ T cell depletion, we further confirmed the relevance of CD8+ T cells for elimination of ferroptotic Gpx4−/− MC38 tumours in Clec9acrePtger2−/−Ptger4fl/fl mice (Extended Data Fig. 10g–i).

Finally, to specifically examine whether pharmacological inhibition of COX-driven PGE2 production can achieve better immune control of ferroptotic tumours, we analysed the growth of Gpx4−/− MC38 tumours transplanted into WT mice with or without CXB treatment. In line with PGE2-mediated impairment of anticancer immunity against ferroptotic tumours, Gpx4−/− MC38 tumours in CXB-treated mice displayed markedly increased control of tumour growth (Fig. 4j). Of note, this effect was associated with prominently enhanced expansion of CD8+ TILs (Fig. 4k), with a high frequency of GZMB-expressing cells (Extended Data Fig. 10j). Similarly, tumours formed by Gpx4−/− BRAF(V600E) melanoma cells exhibited tumour regression in CXB-treated, but not in untreated, WT mice (Extended Data Fig. 10k). Consistent with these data, BRAF(V600E) melanoma tumour-bearing WT mice treated with a combination of CXB and the ferroptosis inducer imidazole ketone erastin (IKE) displayed enhanced tumour growth control compared with untreated mice or mice treated with CXB or IKE alone (Fig. 4l and Extended Data Fig. 10l). Together, these data suggest that PGE2 produced by ferroptotic cancer cells limits anticancer immunity by controlling cDC1-driven effector differentiation and expansion of CD8+ TILs, which enables ferroptotic tumours to escape immune control. Interfering with the PGE2–EP2/EP4 axis can elicit cDC1-mediated expansion and effector differentiation of CD8+ TILs in ferroptotic tumours and result in protective anticancer immunity.

Discussion

Our results demonstrate that ferroptosis in cancer cells triggers aberrant synthesis of the bioactive lipid PGE2, enabling ferroptotic cancer cells to exert deleterious effects on cDC1-dependent, CD8+ TIL-mediated anticancer immunity within tumour tissue. This inhibitory mechanism is critical for immune escape of ferroptotic tumours.

Beyond highlighting that tumour ferroptosis causes suppression of anticancer immunity, as has been recently suggested8,9,10,14,17, our results reveal that this barrier to ferroptosis-inducing strategies mechanistically depends on PGE2 and its signalling through the PGE2 receptors EP2 and EP4, preventing cDC1-mediated expansion and effector differentiation of anticancer CD8+ TILs. As a result, interference with PGE2–EP2/EP4 signalling enhances the anticancer activity of cDC1s in ferroptotic tumours and induces protective, CD8+ TIL-mediated anticancer immunity. These findings therefore identify a molecular mechanism fundamentally linked to the metabolic underpinnings of ferroptosis that may be decisive for ferroptosis-mediated impairment of cancer immunity. Of note, it seems likely that PGE2 from ferroptotic tumour cells not only targets cDC1s but in parallel also interferes directly with anticancer TILs, as indicated by our data. PGE2 may further limit the anticancer activity of other innate immune cells such as type 2 conventional DCs (cDC2s), monocyte–macrophages or natural killer cells41.

We have revealed that PGE2 production by ferroptotic cancer cells involves p38 MAPK signalling activated through lipid peroxidation-induced, membrane permeabilization-dependent Ca2+ influx, which activates a molecular program that causes transcriptional upregulation of the COX–PGE2 pathway. Beyond providing a mechanistic explanation for high COX2 levels in ferroptotic cells, as has been recently observed18,42, our results uncover that this trait acquired by ferroptotic cells is uncoupled from the execution of cell death. As a consequence, interference with p38 MAPK signalling can disable the production of PGE2 while maintaining effective cancer cell elimination by ferroptosis inducers.

Multiple studies have highlighted the vulnerability of therapy-resistant and difficult-to-treat cancers to ferroptosis induction and the dependency of ferroptotic cancer elimination on anticancer immunity. Therefore, our discoveries that ferroptotic tumour cells antagonize anticancer immunity through the PGE2–EP2/EP4 axis and the uncoupling of this mechanism from ferroptosis-mediated tumour cell elimination have important mechanistic and clinical implications. Our results indicate that targeting PGE2–EP2/EP4 signalling to overcome ferroptosis-induced immunosuppression may provide an attractive means to unleash anticancer CD8+ T cell immunity and achieve cancer elimination by ferroptosis-inducing strategies. On this note, abolishing PGE2 production by inhibition of p38 MAPK signalling bears the potential to interfere with the immunosuppressive capacity of ferroptotic cancer cells without curbing ferroptosis-mediated cancer cell elimination. Our findings therefore identify p38 MAPK signalling-induced COX–PGE2 pathway activity in ferroptotic cancer cells as a potential molecular target to prevent immune evasion and improve cancer therapy by ferroptosis-inducing strategies. Of note, disabling the p38 MAPK–COX–PGE2 signalling may further benefit necroptosis-inducing strategies, as indicated by our findings with necroptotic cells.

Methods

Mice

All mice used in this study were on a C57BL/6J genetic background and obtained from Jackson Laboratory (JAX). Ptger2−/−Ptger4fl/fl mice were generated by crossing Ptger2−/− mice (004376, JAX) to Ptger4fl/fl mice (028102, JAX) and further crossed to Clec9acre mice (025523, JAX) to generate Clec9acrePtger2−/−Ptger4fl/fl mice, crossed to Cd4cre mice (022071, JAX) to generate Cd4crePtger2−/−Ptger4fl/fl mice or crossed to Itgaxcre mice (008068, JAX) to generate ItgaxcrePtger2−/−Ptger4fl/fl mice. OT-I × CD45.1 mice were generated by crossing OT-I mice (003831, JAX) to CD45.1 (002014, JAX) mice. Unless stated otherwise, all mice used in this study were used on a CD45.2/CD45.2 background. In all experiments, mice at 8–20 weeks of age were sex matched and randomly assigned to control or treatment groups. Mouse tumour experiments with Gpx4−/− tumours as well as T cell depletion were conducted without blinding; all other experiments were conducted in a blinded manner. No statistical methods were used to predetermine sample sizes. Mice were killed by cervical dislocation under anaesthesia. All mice were maintained and bred at the Technical University of Munich Klinikum rechts der Isar, under specific-pathogen-free, standard conditions with water and food ad libitum, in a controlled environment (22 ± 2 °C, 55 ± 10% humidity, 12 h light–dark cycle) and in accordance with the guidelines of the Federation of European Laboratory Animal Science Associations. All animal experiments were performed in accordance with the guidelines of the District Government of Upper Bavaria (Department 5–Environment, Health and Consumer Protection).

Cell lines

Control and Ptgs1/Ptgs2−/− BRAF(V600E) melanoma cells were generated using the CRISPR–Cas9 system as previously described21. BRAF(V600E)–OVA and Ptgs1/Ptgs2−/− BRAF(V600E)–OVA variants were generated by lentiviral transduction, as previously described20. 4-OH-TAM-inducible Gpx4−/− mouse immortalized fibroblasts (Pfa1) have been previously described43. Gpx4−/− MC38 and Gpx4−/− BRAF(V600E) cells were generated by CRISPR–Cas9-mediated gene editing using the lentiCRISPR v2-puro vector expressing single guide RNAs, as previously described44. In brief, Gpx4-targeting single guide RNA (5′-caccGCGTGTGCATCGTCACCAACG) was cloned in the BsmBI-digested lentiCRISPR v2-puro vector (98290, Addgene) and used to transiently transfect cancer cell lines using the X-tremeGENE HP agent (Roche). One day after transfection, cells were selected using puromycin (5 µg ml−1) and further cultivated with Lip-1 (1 µM) to prevent ferroptosis. After selection, single-cell clones were picked, and knockout clones were identified by immunoblotting. Mapk14−/− cells were generated by CRISPR–Cas9-mediated gene editing using the p38α MAPK14 CRISPR–Cas9 knockout plasmid (sc-424051; Santa Cruz) according to manufacturer’s protocol. After sorting for GFP+ cells, single-cell clones were picked, and knockout clones were identified by immunoblotting. Pfa1, Lewis lung carcinoma (LLC) and Gpx4−/− LLC cells were provided by M.C.; MC38 and Su86.86 cells were provided by A. Krüger. small-cell lung cancer (SCLC) cell lines were provided by S.v.K.

BRAF(V600E), Ptgs1/Ptgs2−/− BRAF(V600E), BRAF(V600E)–OVA, Ptgs1/Ptgs2−/− BRAF(V600E)–OVA, 4T1, NRAS(G12D), LLC, CT26, SLCL, Pfa1, NIH3T3, A549, Su86.86 and HT-29 cells were cultured in complete RPMI medium (RPMI 1640 medium, Thermo Fisher Scientific) supplemented with 10% FCS (PAN-Biotech), 50 U ml–1 penicillin (Thermo Fisher Scientific) and 50 µg ml–1 streptomycin (Thermo Fisher Scientific). MC38, D4M.3 A, Panc02, mouse pancreatic ductal adenocarcinoma (PDAC) and human patient-derived PDAC cells were cultured in DMEM (Thermo Fisher Scientific) supplemented with 10% FCS, 50 U ml–1 penicillin and 50 mg ml–1 streptomycin. Gpx4−/− cells were cultured in their respective medium supplemented with 1 μM Lip-1 to prevent ferroptosis. For in vitro assays, Gpx4−/− cell lines were cultivated in 1 µM Ferrostatin-1 (Fer-1) for one passage before seeding them with or without Fer-1 to assess ferroptosis and PGE2 production. Unless stated otherwise, all analyses of cell viability and PGE2 production were performed after 24 h.

To generate cancer cell conditioned medium, 4 × 105 cancer cells were cultured in 2 ml complete RPMI medium or DMEM for 24 h before addition of the ferroptosis inducers RSL3 or ML210 (250 nM for NRAS(G12D), 500 nM for 4T1 and D4M.3A, and 1,000 nM for BRAF(V600E) and MC38 cells), doxorubicin (10 µM) or treatment with 150 mJ cm−2 UVB. 8 h later, cancer cells were washed three times with PBS and cultivated for another 16 h in complete RPMI or DMEM. The cell supernatant was collected, centrifuged at 600g for 5 min to remove dead cell debris and stored at −20 °C until further use. All cell lines were routinely tested for mycoplasma contamination in-house by PCR. No further cell line authentications were conducted in the laboratory.

Tumour cell injections

Cancer cell lines were detached by trypsinization (Thermo Fisher Scientific) and washed three times in sterile PBS (Thermo Fisher Scientific). Cells were injected subcutaneously in 100 μl endotoxin-free PBS on the flank of recipient mice, using 2 × 105 cells for tumour growth studies and 2 × 106 cells for all other experiments. Tumour growth was measured using a digital calliper. Tumour diameters stated in the figures refer to the average values of the longest diameter and its perpendicular for each tumour. Tumour growth was restricted to a maximum diameter of 15 mm, which served as the humane end point and was not exceeded in any of the experiments. For animals reaching the humane end point before the end of the observation period, the last measured tumour diameter was carried forwards to subsequent time points (last observation carried forwards). For experiments involving ferroptotic control or Ptgs1/Ptgs2−/− BRAF(V600E)–OVA melanoma cells, cancer cells were pre-treated with 1 μM RSL3 for 8 h before subcutaneous injection of 1 × 106 cells in 100 μl of endotoxin-free PBS into the flank of recipient mice.

CD8+ T cell depletion in vivo

To deplete CD8+ T cells, mice received intraperitoneal injections of 100 µl anti-mouse CD8β antibody (200 µg per mouse; 53-5.8, BioXCell) every 5 days, beginning on day 1 following tumour cell inoculation.

Pharmacological treatment in vivo

Treatment of mice bearing subcutaneous MC38 or control BRAF(V600E) tumours was initiated once tumours were palpable, on days 3–5 post-tumour cell transplantation. Solutions were prepared fresh every day. For induction of ferroptosis, mice received daily intraperitoneal injection of 40 mg kg−1 IKE dissolved in 55% PEG 300 (Sigma) and 45% PBS. Lyophilized CXB (MedChem) was weighed using a fine balance and made up in a 60:40 ratio of DMSO (1 part, Sigma)/PEG400 (5 parts, Sigma):dH2O. The final concentration was 6 mg ml−1, corresponding to a dose of 30 mg kg−1 delivered in a total volume of 100 µl per mouse. CXB was administered daily by oral gavage.

Processing of tumour tissue and lymphoid organs

Tumours, lymph nodes or spleens of tumour cell-inoculated mice were collected at the indicated time points after cancer cell transplantation. Tumour or organ weight was measured using a microscale. For flow cytometry analysis, tumour samples were mechanically dissociated and digested with DNase I (100 µg ml–1, Merck) and collagenase IV (200 U ml–1, Thermo Fisher Scientific) for 40 min at 37 °C followed by filtration through a 70-µm and a 30-µm cell strainer (Miltenyi) and washing with FACS buffer (PBS with 1% FCS and 2 mM EDTA) to generate single-cell suspensions before proceeding with antibody-mediated staining. Spleens were passed through a 70-µm cell strainer, followed by red blood cell lysis with ACK-lysis buffer for 3 min and additional filtration using a 30-µm cell strainer. Lymph nodes were dissociated using a 30-µm cell strainer.

Antibodies and reagents for flow cytometry and cell sorting

The following antibodies and staining reagents were used for flow cytometry or cell sorting: fixable viability dye eFluor 450 (dilution: 1:1,000; Thermo Fisher Scientific); fixable viability dye APC-eF780 (1:2,000; Thermo Fisher Scientific); PE-Cy7 anti-CD8α (1:200; 53-6.7, BioLegend); PE-Dazzle594 anti-CD8α (1:200; 53-6.7, BioLegend); BV711 anti-mouse/human-CD44 (1:100; IM7, BioLegend); PerCP-Cy5.5 anti-mouse/human-CD44 (1:100; IM7, BioLegend); PE anti-CD45.1 (1:100; A20, BioLegend); BV510 anti-CD45.2 (1:100; 104, BD Biosciences); BUV395 anti-CD45.2 (1:100; 104, BD Biosciences); FITC anti-CD62L (1:100; MEL-14, BioLegend); FITC anti-CD103 (1:100; M290, BD Biosciences); Pe-Cy7 anti-CD103 (1:100; 2E7; BioLegend); PE-Dazzle594 anti-CD186/CXCR6 (1:200; SA051D1, BioLegend); BV421 anti-CD366/TIM-3 (1:200; RMT3-23, BioLegend); BV605 anti-CD279/PD-1 (1:100; 29F.1A12, BioLegend); PerCP/Cy5.5 anti-TCRβ (1:100; H57-597, BioLegend); AF700 anti-TCRβ (1:100; H57-597, Sony); APC anti-human GZMB (1:200; GB12, Thermo Fisher Scientific); PE anti-human GZMB (1:200; GB12; Thermo Fisher Scientific); FITC anti-Ki-67 (1:100; SolA-15, Thermo Fisher Scientific); PE anti-mouse TCF1 (1:200; S33-966, BD Biosciences); and rabbit-anti-mouse-TCF1/TCF7 (1:100; C.725.7, Thermo Fisher Scientific). This was followed by staining with AF647 donkey-anti-rabbit IgG (1:200; Poly4064, BioLegend); BV605 anti-CD11b (1:200; M1/70; BioLegend); PerCP-Cy5.5 anti-CD11c (1:200; N418; BioLegend); PE-Cy7 anti-CD11c (1:200; M17/4; BioLegend); BV421 anti-XCR1 (1:200; ZET; BioLegend); PE anti-CXCL9 (1:100; MIG-2F5.5, BioLegend); PerCP/Cy5.5 anti-IL-12/IL-23 p40 (1:100; C15.6, BioLegend); FITC anti-I-A/I-E (MHC class II) (1:1,000; M5/114.15.2, Thermo Fisher Scientific); AF700 anti-mouse H-2kb (1:100; AF6-88.5, BioLegend); AF647 anti-CD86 (1:200; GL-1, BioLegend); BV605 anti-CD80 (1:200; 16-10A1, BioLegend); and BV421 anti-CD3 (1:200; 17A2, BioLegend).

Flow cytometry and cell sorting

Staining of the cell surface with fluorescently labelled antibodies and viability dyes was performed for 20 min at 4 °C in FACS buffer (PBS with 1% FCS and 2 mM EDTA). For intracellular staining of GZMB, TCF1 and Ki-67, cells were fixed and permeabilized using the True-Nuclear Transcription Factor Buffer Set (BioLegend) according to the manufacturer’s protocol. Intracellular staining of CXCL9 or IL-12 was performed using the Intracellular Fixation & Permeabilization Buffer Set (Thermo Fisher) according to the manufacturer’s protocol. Intracellular staining was performed overnight in permeabilization buffer at 4 °C. Flow cytometry analyses were performed using a ID7000C Spectral Cell Analyzer (ID7000 software v2.0.2.17121, Sony Biotechnologies) or a SP6800 Spectral Cell Analyzer (spectral analyser software v2.0.2.14140, Sony Biotechnologies). Flow cytometric quantification of cell numbers was done using CountBright Absolute Counting Beads (Thermo Fisher Scientific). All flow cytometric data were analysed using FlowJo (v10.10.0, BD Biosciences). Sorting of naive OT-I T cells (CD45.1+CD8+CD62L+CD44–) from blood for adoptive transfer experiments and mouse cDC1s (CD103+) from bone marrow cultures was performed using a SH800S Cell Sorter (cell sorter software v2.1.6, Sony Biotechnologies). Representative flow cytometry-gating strategies for analyses of CD8+ TILs, intratumoural cDC1s and cDC2s or splenic cDC1s and cDC2s can be found in Supplementary Fig. 1.

Adoptive T cell transfer of OT-I T cells

For adoptive transfer of OVA-specific OT-I cells, 1 × 103 congenically marked naive CD8+ T cells (CD45.1+CD8+CD62L+CD44−) were isolated from the blood of OT-I donor mice and injected intravenously into sex-matched CD45.2+ recipient mice in 100 µl sterile PBS. The transfer was performed 6 h before subcutaneous transplantation of ferroptotic control or Ptgs1/Ptgs2−/− BRAF(V600E)–OVA melanoma cells.

Immunofluorescence microscopy and image analysis

Volumetric immunofluorescence tumour microscopy was performed as previously described45. In brief, tumours were fixed in Antigenfix solution (Diapath). Samples were dehydrated in 30% sucrose, embedded in TissueTek OCT freezing medium (Sakura Finetek) and stored at −80 °C. Consecutive sections of 50 μm thickness were generated using a Leica CM3050 S cryostat. Sections were permeabilized, blocked and stained in 0.1 M Tris (Carl Roth) supplemented with 1% BSA, 0.3% Triton X-100 (Merck), normal mouse serum (Merck) and donkey serum (Merck). Stained sections were mounted in Mowiol (Merck) and analysed using an inverted TCS SP8 confocal microscope (Leica), a STELLARIS confocal microscope (Leica) or a THUNDER imager (Leica) for tiled imaging using a HC PL APO CS2 ×20/0.75 NA objective or a HC PL APO CS2 ×40/1.30 NA THUNDER objective, or a Fluoview FV3000 microscope using an UPlanSApo ×20 air/0.75 NA objective (Olympus). All images were acquired as tiled image stacks, covering whole-tumour sections in the xy plane, with 2-μm z-spacing to provide large three-dimensional (3D) image volumes of at least 20 μm depth. Image analysis and cell rendering was performed as previously described45. 3D images were analysed using the Imaris 10.2.0 software (Oxford Instruments). The Imaris surface generation tool was used to reconstruct and visualize 3D objects for individual cells. Clusters of interacting cDC1s and CD8+ T cells were identified in a multi-step process using positional information for cell objects. CD8+ T cell clusters were defined as a minimum of five cells within a distance of 20 μm measured from the outer surface of each cell and identified using the Imaris built-in ‘distance to 5 nearest neighbours’ function. cDC1s interacting with clustered CD8+ T cells (referred to as ‘interacting cDC1’) were identified using object–object closest distance (distance ≤ 5 μm). To identify clustered CD8+ T cells interacting with cDC1s (‘interacting CD8+ T cells’), CD8+ T cells localized more than 15 μm from these interacting cDC1s were removed by distance thresholding using the Imaris filter function. Quantification of cell clusters was performed relative to the volume of the imaged section.

Antibodies for immunofluorescence microscopy

The following antibodies were used for staining of mouse tissues: AF594 anti-CD3 (1:200; clone 17A2, BioLegend), BV421 anti-CD8α (1:100; clone 53-6.7; BioLegend), anti-CD103 (1:200; goat polyclonal; R&D Systems), FITC anti-MHC class II I-A/I-E (1:500; clone M5/114.15.2, BioLegend), AF680 anti-goat IgG (1:500; donkey polyclonal; Jackson ImmunoResearch), anti-COX2 (1:200; amino acids 584–598; Cayman Chemicals) and AF647 anti-rabbit IgG (1:400; A-21244, Invitrogen). All antibodies were either validated by the manufacturer or were previously reported for immunofluorescence microscopy.

Live-cell imaging

Live-cell imaging was performed using a DMi8 microscope (Leica) with a HC PL APO ×20/0.8 PH2 or HC PL APO ×40/0.95 CORR PH2 objective. Temperature was regulated at 37 °C and CO2 level at 5% using a Heating Unit 2000 (Pecon) equipped with a TempController 2000 (Pecon) and CO2-Controller 2000 (Pecon). Pfa1 cells (2 × 104) were seeded in a µ-slide glass-bottom chamber slide (Ibidi) and cultivated for 24 h before imaging. Dyes for the staining of lipid peroxidation using BODIPY C11 (2 µM; Thermo Fisher Scientific), Ca2+ influx using Fluo-8-AM (4 µM; AAT Bioquest) or CalBryte 630-AM (5 µM; AAT Bioquest), small-molecule influx using FITC-labelled dextrans of 4 kDa or 70 kDa and membrane permeabilization as a marker for cell death using Sytox blue (5 µM; Thermo Fisher Scientific) or 7-AAD (1:40; Thermo Fisher Scientific) were added 30 min before imaging and kept in the media for the time of imaging. To assess lipid peroxidation by BODIPY staining, BODIPY 581/591 C11 (Thermo Fisher) was added directly into the cell culture media at a final concentration of 2 µM and cells were incubated for 30 min at 37 °C before being washed three times with PBS. For live-cell microscopy-based single-cell analyses, BODIPY C11 was kept in the media for the time of imaging. Measurement of oxidized BODIPY C11 was performed after excitation by a 488 nm laser, and measurement of non-oxidized BODIPY C11 after excitation with a 581 nm laser.

Immunohistochemistry of tumour tissue

For immunohistochemistry, formalin-fixed and paraffin-embedded tumour tissue sections were heated at 60 °C for 15 min and deparaffinized with xylene and graded ethanol. Sections were washed in TBS containing 0.01% Tween-20 (TBS-T) and blocked with 5% normal goat serum in TBS-T for 20 min at room temperature. Sections were then incubated overnight at 4 °C with mouse monoclonal anti-4-HNE antibody (1:200; HNEJ-2, JaICA) diluted in TBS-T containing 5% goat serum. After three washes in TBS-T, endogenous peroxidase activity was quenched by incubation with 0.3% H2O2 in methanol for 20 min, followed by three washes in TBS-T. Sections were incubated with biotinylated goat anti-mouse IgG secondary antibody (1:200; 115-065-166, Jackson ImmunoResearch) in TBS-T containing 5% goat serum for 30 min at room temperature, followed by incubation with the VECTASTAIN Elite ABC peroxidase system (PK-6100, Vector Laboratories) for 30 min at room temperature. After washing, sections were visualized using DAB substrate (SK-4100, Vector Laboratories), with development monitored microscopically until a suitable brown colour was obtained. The reaction was stopped by washing with water, and sections were counterstained with haematoxylin, blued in tap water, dehydrated through graded ethanol and xylene, and mounted in Roti Mounting medium (Carl Roth).

cDC1 assays

Generation of cDC1s was performed as previously described19, with minor modifications. In brief, bone marrow cells were isolated from mouse femur and tibia by flushing the bones with RPMI using a syringe and a 20-gauge cannula. After red blood cell lysis using ACK buffer (double-distilled H2O (ddH2O) with 150 mM ammonium chloride, 10 mM potassium bicarbonate and 1μm disodium EDTA) for 3 min at room temperature, 1.5 × 106 cells per millilitre were incubated with GM-CSF (300 pg ml−1) and FLT3L (55 ng ml−1) in RPMI 1640 medium (Thermo Fisher Scientific) supplemented with 10% FCS (PAN-Biotech), 50 µM β-mercaptoethanol (Thermo Fisher Scientific), 50 U ml–1 penicillin (Thermo Fisher Scientific) and 50 µg ml–1 streptomycin (Thermo Fisher Scientific). After 9 days of culture, non-adherent cells were reseeded at 0.3 × 106 cells per millilitre in fresh medium containing GM-CSF and FLT3L for an additional 5 days before FACS sorting of differentiated cDC1s based on CD103 expression. For assays using splenic cDCs, freshly isolated mouse spleens were digested in RPMI 1640 containing DNase I (100 µg ml–1; Merck) and collagenase IV (200 U ml–1; Thermo Fisher Scientific) for 30 min. Dendritic cells were subsequently isolated using the Pan Dendritic Cell Isolation Kit, mouse (130-100-875, Miltenyi Biotec), according to the manufacturer’s protocol.

For in vitro treatment with cancer cell conditioned medium, mouse cDC1s were cultured with conditioned medium from cancer cells at 37 °C for 16 h before their analysis or use in functional assays. For assessment of cytokine and chemokine production following activation, cDC1s were stimulated with poly(I:C) (10 μg ml−1) for 4 h, and brefeldin A (5 μg ml−1) was added for the last 3 h of stimulation before proceeding with antibody staining for flow cytometric analyses. In some experiments, cDC1 stimulation was done using IFNγ (10 ng ml−1), IFNα (10 ng ml−1), 2′,3′-cGAMP (10 μM), NAD (10 μM) or ATP (100 μM). For the generation of cDC1 conditioned medium, cDC1s were first treated with cancer cell conditioned medium for 16 h, washed three times with PBS and stimulated with poly(I:C) (10 μg ml−1) for 24 h. The culture supernatant was collected and centrifuged at 600g for 5 min to remove remaining cell material, and the cell-free conditioned medium was collected and stored at −20 °C until further use.

Analysis of cDC1-mediated CD8+ T cell expansion

To generate antigen-experienced stem-like CD8+ T cells, naive CD8+ T cells were isolated from the spleens of mice using MACS separation and stimulated with mouse anti-CD3/CD28 microbeads and IL-2 (85 U ml–1) for 4 days. After 2 days of culture, CD8+ T cells were re-seeded at 1 × 106 cells per millilitre with fresh medium containing anti-CD3/28 microbeads plus IL-2. To assess the ability of cDC1s to promote antigen-experienced CD8+ T cell expansion, 2.5 × 104 CD8+ T cells from T cell cultures were incubated with mouse anti-CD3/CD28 microbeads in the presence or absence of supernatant from cDC1s pre-treated as indicated in the figure legends. After 72 h of incubation, the number of viable CD3+CD8+ T cells was quantified by flow cytometry.

Cell viability assay

Resazurin (7-hydroxy-10-oxidophenoxazin-10-ium-3-one, sodium; Stemcell) was added directly to the culture medium at a final concentration of 50 µg ml−1 and incubated for 1 h at 37 °C. Viability was measured at an excitation/emission wavelength of 540/590 nm using a Tecan infinite M1000Pro and Tecan i-control software (v3.9.1.0). Cell viability was calculated as the percentage of fluorescence intensity relative to the vehicle control group.

PGE2 measurements

PGE2 concentration in cell-free conditioned medium was measured by enzyme-linked immunosorbent assay (ELISA) (Cayman Chemical) according to the manufacturer’s protocol using a Tecan infinite M1000Pro and Tecan i-control software (v3.9.1.0).

Measurement of cDC1 cytokine production

Cytokine and chemokine concentrations in conditioned medium from stimulated cDC1s were quantified using the LEGENDplex bead-based multiplex immunoassay (BioLegend) according to the manufacturer’s protocol.

Blockade of Ca2+ influx

To block the influx of extracellular Ca2+ into ferroptotic cells, the calcium-chelator EGTA (2 mM) or the osmoprotectant PEG 3350 (10 mM) was added to the cell culture media 4 h after cancer cell treatment with the ferroptosis inducer RSL3.

Western blotting

Cells were lysed in RIPA lysis buffer (150 mM NaCl, 5 mM EDTA, 50 mM Tris, 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS in ddH20) containing protease and phosphatase inhibitor cocktail (Sigma-Aldrich), sonicated three times for 10 s at 35 kHz and centrifuged at 15,000g at 4 °C for 5 min. The supernatant was collected and used as the protein sample. Western blotting was performed by standard immunoblotting procedure with 12% SDS–PAGE gel and nitrocellulose membrane. Primary antibody staining to GPX4 (1:2,000; EPNCIR144, Abcam), COX2 (1:1,000; amino acids 584–598; Cayman Chemical), β-actin (1:2,000; #4967S, Cell Signaling), p38 (1:1,000; #9212S, Cell Signaling), phospho-p38 (1:1,000; D3F9, Cell Signaling), p38α (1:1,000; #9218S, Cell Signaling) or HSP60 (1:2,000; D6F1, Cell Signaling) was performed at 4 °C overnight. Horseradish peroxidase-labelled secondary antibodies to mouse IgG (1:10,000; RRID: AB_10015289, Jackson ImmunoResearch) or rabbit IgG (1:10,000; RRID: AB_2313567, Jackson ImmunoResearch) were stained for 1 h at room temperature. Bands were visualized using Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific). Images were taken with a ChemiDoc XRS+ (Bio-Rad). Images were analysed with Image Lab software (v6.0.1; Bio-Rad). Images of all uncut blots can be found in Supplementary Fig. 2.

Liquid chromatography with tandem mass spectrometry-based lipid profiling

Cell-free conditioned media from cancer cells were mixed 1:1 with methanol (50% v/v) immediately after collection and stored at −80 °C. For analysis, 200 µl of each sample was thawed on ice, spiked with 10 µl of an internal standard mix (final concentration of 5 ng ml−1) and precipitated with 50 µl cold methanol (−20 °C). After protein denaturation on ice (10 min) and centrifugation (10,000g for 15 min at 4 °C), supernatants were adjusted to 1 ml with Milli-Q water. Eicosanoids were extracted using Strata-X 33-µm polymeric reversed-phase SPE plates (Phenomenex) on a Positive Pressure-96 Processor (Waters). Columns were conditioned with methanol and water, and samples were loaded and washed with 10% methanol. Target analytes were eluted in 100% methanol. Eluates were evaporated under nitrogen at 30 °C and reconstituted in 30 µl of 50% methanol. Ten microlitres were injected onto a Sciex QTRAP 6500+ mass spectrometer associated with an Exion UHPLC operated in negative-ion mode using scheduled multiple reaction monitoring. Quantification was carried out using calibration curves and internal standards, with quality control pools and blank samples analysed throughout the run to ensure accuracy and reproducibility. For BRAF(V600E), NRAS(G12D), 4T1 and MC38 cancer cell lines, fold change of each analyte production during ferroptosis relative to DMSO control group was plotted against its final concentration in ferroptotic conditioned medium. For Pfa1 cells, analytes from each oxylipin subclass (eicosanoid, hydroxylated/oxidized lipids and protectins/resolvins) were ordered from high to low abundance in ferroptotic-conditioned medium and plotted as a z-score between different treatment groups.

RNA isolation and quantitative real-time PCR

RNA was isolated using Monarch Total RNA Miniprep kit (New England Biolabs) and complementary DNA (cDNA) was generated using a SensiFAST cDNA synthesis kit (Bioline). Quantitative real-time PCR was performed on a LightCycler 480 (LightCycler 480 software v1.5.1, Roche) using the TAKYON No ROX SYBR MasterMix dTTP Blue kit (Eurogentec) according to the manufacturer’s protocol. Gene expression was normalized to the reference gene Hprt by using the ΔCt method. All primers were purchased from Eurofins.

RNA sequencing

In vitro-generated WT or ItgaxcrePtger2−/−Ptger4fl/fl CD103+ cDC1s were incubated for 16 h with conditioned medium from control or Ptgs1/Ptgs2−/− ferroptotic BRAF(V600E) melanoma cells followed by stimulation with poly(I:C) (10 μg ml−1) for an additional 4 h. RNA was isolated using an Arcturus PicoPure RNA isolation kit (Thermo Fisher Scientific). Library preparation was carried out using the Novogene manufactured internal kit. mRNA was purified from total RNA using poly-T oligo-attached magnetic beads. After fragmentation, the first strand cDNA was synthesized using random hexamer primers, followed by the second strand cDNA synthesis using dUTP for directional (strand-specific) library construction. Sequencing was performed on a NovaSeq X Plus with 25B flowcell 2 × 150 bp paired-end sequencing (300 cycles kit). The raw fastq files related to the sequence reads were mapped to the mouse genome, which was downloaded from the UCSC browser (GRCm38/mm10), using the STAR algorithm46. The reads were counted using the Rsubread R package47. These read counts were normalized, and differentially expressed genes were analysed using the iDEP (v2.01) web server48, utilizing the DESeq2 R package49 for differentially expressed gene identification (with fold change ≥ 1.5 and adjusted P < 0.05). Principal component analysis was performed using the prcomp R function and plotted using the ggplot2 R package. Volcano plots were rendered using the Enhanced Volcano R package (https://github.com/kevinblighe/EnhancedVolcano). The ‘Core functional cDC1’ gene set was defined as activation-induced genes significantly downregulated in activated cDC1s following incubation with conditioned medium from ferroptotic control BRAF(V600E) cells. Hierarchical clustering of core functional cDC1 genes was performed using the hclust function in R (Euclidean distance, complete linkage), and heatmaps were generated using the heatmap.2 function of the gplots R package. Gene set enrichment analysis (GSEA) was performed on core functional cDC1 genes and arranged according to log2(fold changes). Enrichment of gene sets was then conducted using GSEA (v4.2.3)50. Gene sets related to cytokine signalling and cell migration were extracted from the Molecular Signature Database (https://www.gsea-msigdb.org/gsea/msigdb/index.jsp). Gene signatures for antigen uptake and cross-presentation were from a previous study51. The gene set for PGE2 impaired functional cDC1 genes was from a previous study19. PGE2-impaired core functional cDC1 genes for correlation analysis were defined as activation-induced genes significantly downregulated in activated cDC1s following incubation with PGE2. The PreRanked tool from GSEA (v4.2.3) was used to assess the normalized enrichment score, and a false discovery rate (q < 0.25) was utilized to evaluate the statistical significance of the normalized enrichment score.

Statistics and reproducibility

Throughout this study, different statistical tests were used to assess statistical significance, as indicated in the figure legends. Data are shown as the mean ± s.e.m., mean ± minimum and maximum values or boxplots, as indicated in the figure legends.

Data shown in Figs. 1e and 3g are pooled from two independent experiments. Data shown in Figs. 1b,d, 2b,c,h–k,m–q, 3f,i and 4d,g are representative of two independent experiments. For the boxplots in Figs. 1b, 2h–k,m–o and 3i, the centre line indicates the mean and the bounds show the minimum and maximum values. For the boxplots in Figs. 1e and 4c,e,f,h,i,k, the centre line indicates the median, the bounds extend from the 25th to 75th percentiles and the whiskers correspond to the minimum and maximum values. GraphPad Prism software (v9.5.0 and v9.5.1) was used for statistical analyses.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

RNA sequencing data generated in this study, including raw sequencing reads (FASTQ files) and processed count data, have been deposited in the Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/gds) under the accession code GSE346455. The pre-built mouse reference genome GRCm38/mm10 was obtained from the UCSC Genome Browser (https://hgdownload.soe.ucsc.edu/goldenPath/mm10/bigZips/). The cytokine signalling gene set was obtained from the Molecular Signatures Database (v2023.1.Mm, Subramanian et al.50; https://www.gsea-msigdb.org/gsea/msigdb). The cell migration gene set was custom compiled and obtained from a previous study19. Gene signatures for antigen uptake and cross-presentation were obtained from Kelly and Trowsdale51. The gene set for PGE2-impaired functional cDC1 genes was obtained from Bayerl et al.19. Lists for all gene sets used for GSEA can be found in Supplementary Table 3. Source data are provided with this paper.

References

  1. Viswanathan, V. S. et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547, 453–457 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Hangauer, M. J. et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551, 247–250 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Tsoi, J. et al. Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress. Cancer Cell 33, 890–904.e5 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Schwab, A. et al. Zeb1 mediates EMT/plasticity-associated ferroptosis sensitivity in cancer cells by regulating lipogenic enzyme expression and phospholipid composition. Nat. Cell Biol. 26, 1470–1481 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Dixon, S. J. & Olzmann, J. A. The cell biology of ferroptosis. Nat. Rev. Mol. Cell Biol. 25, 424–442 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Berndt, C. et al. Ferroptosis in health and disease. Redox Biol. 75, 103211 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Cañeque, T. et al. Activation of lysosomal iron triggers ferroptosis in cancer. Nature 642, 492–500 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Nakamura, T. & Conrad, M. Exploiting ferroptosis vulnerabilities in cancer. Nat. Cell Biol. 26, 1407–1419 (2024).

    Article  CAS  PubMed  Google Scholar 

  9. Lei, G., Zhuang, L. & Gan, B. Targeting ferroptosis as a vulnerability in cancer. Nat. Rev. Cancer 22, 381–396 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Wiernicki, B. et al. Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity. Nat. Commun. 13, 3676 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Li, J. et al. Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer. Sci. Transl. Med. 15, eadg3049 (2023).

    Article  CAS  PubMed  Google Scholar 

  12. Wang, W. et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 569, 270–274 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Liao, P. et al. CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell 40, 365–378.e6 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Kim, R. et al. Ferroptosis of tumour neutrophils causes immune suppression in cancer. Nature 612, 338–346 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Conrad, M. & Pratt, D. A. The chemical basis of ferroptosis. Nat. Chem. Biol. 15, 1137–1147 (2019).

    Article  CAS  PubMed  Google Scholar 

  16. Wahida, A. & Conrad, M. Decoding ferroptosis for cancer therapy. Nat. Rev. Cancer 25, 910–924 https://doi.org/10.1038/s41568-025-00864-1 (2025).

  17. Angeli, J. P. F., Krysko, D. V. & Conrad, M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat. Rev. Cancer 19, 405–414 (2019).

    Article  Google Scholar 

  18. Yapici, F. I. et al. An atlas of ferroptosis-induced secretomes. Cell Death Differ. 32, 1986–2008 https://doi.org/10.1038/s41418-025-01517-4 (2025).

  19. Bayerl, F. et al. Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses. Immunity 56, 1341–1358.e11 (2023).

    Article  CAS  PubMed  Google Scholar 

  20. Lacher, S. B. et al. PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells. Nature 629, 417–425 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Zelenay, S. et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162, 1257–1270 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Böttcher, J. P. & Reis e Sousa, C. The role of type 1 conventional dendritic cells in cancer immunity. Trends Cancer 4, 784–792 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  23. Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F. & Sancho, D. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 20, 7–24 https://doi.org/10.1038/s41577-019-0210-z (2020).

    Article  CAS  PubMed  Google Scholar 

  24. Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31, 711–723.e4 (2017).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Roberts, E. W. et al. Critical role for CD103+/CD141+ dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell 30, 324–336 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Meiser, P. et al. A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity. Cancer Cell 41, 1498–1515.e10 https://doi.org/10.1016/j.ccell.2023.06.008 (2023).

  27. Broz, M. L. et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26, 638–652 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Galassi, C., Chan, T. A., Vitale, I. & Galluzzi, L. The hallmarks of cancer immune evasion. Cancer Cell 42, 1825–1863 https://doi.org/10.1016/j.ccell.2024.09.010 (2024).

  29. Chow, M. T. et al. Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy. Immunity 50, 1498–1512.e5 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Ruffell, B. et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 26, 623–637 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Nutt, S. L. & Chopin, M. Transcriptional networks driving dendritic cell differentiation and function. Immunity 52, 942–956 https://doi.org/10.1016/j.immuni.2020.05.005 (2020).

    Article  CAS  PubMed  Google Scholar 

  32. Hammer, G. E. & Ma, A. Molecular control of steady-state dendritic cell maturation and immune homeostasis. Annu. Rev. Immunol. 31, 743–791 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Angeli, J. P. F. et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 16, 1180–1191 (2014).

    Article  Google Scholar 

  34. Pedrera, L. et al. Ferroptotic pores induce Ca2+ fluxes and ESCRT-III activation to modulate cell death kinetics. Cell Death Differ. 28, 1644–1657 (2021).

    Article  CAS  PubMed  Google Scholar 

  35. Riegman, M. et al. Ferroptosis occurs through an osmotic mechanism and propagates independently of cell rupture. Nat. Cell Biol. 22, 1042–1048 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Kalinski, P. Regulation of immune responses by prostaglandin E2. J. Immunol. 188, 21–28 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Siddiqui, I. et al. Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 195–211.e10 (2019).

    Article  CAS  PubMed  Google Scholar 

  38. Miller, B. C. et al. Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. Nat. Immunol. 20, 326–336 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Kurtulus, S. et al. Checkpoint blockade immunotherapy induces dynamic changes in PD-1−CD8+ tumor-infiltrating T cells. Immunity 50, 181–194.e6 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Prokhnevska, N. et al. CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. Immunity 56, 107–124.e5 (2023).

    Article  CAS  PubMed  Google Scholar 

  41. Müller, E., Kruse, B. & Böttcher, J. P. Prostaglandins in cancer revisited: principles of production, mechanisms of immune regulation, and therapeutic perspectives. Blood 147, 713–724 (2026).

    Article  PubMed  Google Scholar 

  42. Yang, W. S. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317–331 (2014).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Seiler, A. et al. Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent- and AIF-mediated cell death. Cell Metab. 8, 237–248 (2008).

    Article  CAS  PubMed  Google Scholar 

  44. Mishima, E. et al. A non-canonical vitamin K cycle is a potent ferroptosis suppressor. Nature 608, 778–783 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Bayerl, F. et al. Guidelines for visualization and analysis of DC in tissues using multiparameter fluorescence microscopy imaging methods. Eur. J. Immunol. 53, 2249923 https://doi.org/10.1002/eji.202249923 (2023).

  46. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2012).

    Article  PubMed  PubMed Central  Google Scholar 

  47. Liao, Y., Smyth, G. K. & Shi, W. The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. Nucleic Acids Res. 47, e47 (2019).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Ge, X. RNA bioinformatics. Methods Mol. Biol. 2284, 417–443 (2021).

    Article  CAS  PubMed  Google Scholar 

  49. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  50. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Kelly, A. & Trowsdale, J. Genetics of antigen processing and presentation. Immunogenetics 71, 161–170 (2019).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank members of the Department of Experimental Immunology, University of Tübingen and the Institute of Immunology, TU Munich for helpful discussions and suggestions; C. Reis e Sousa and R. Marais for kindly sharing the BRAF(V600E) cell lines; T. Mempel for the D4M.3A cells; A. Krüger for the MC38 and Su86.86 cells; B. Schraml for Clec9acre mice; T. Papagiannakopoulos for advice; and the Core Facility Metabolomics of the Medical Faculty of the University of Tübingen and the Helmholtz Munich Core Facility Metabolomics and Proteomics for technical support.

Funding

This work was supported by the German Research Foundation (DFG; project numbers: SPP-2306–461704785; SFB-1479–441891347-P21; 424926990; 442405234; 449174900; 591572118 and 591572002 awarded to J.P.B.; SPP-2306-461704389 and CRC1403-414786233 to S.v.K.; 467868227 to N.S.; TRR-353/1–471011418 to G.E.; and under the Germany’s Excellence Strategy, EXC 2180–390900677 Cluster of Excellence iFIT ‘Image-Guided and Functionally Instructed Tumor Therapies’, the Wilhem Sander-Stiftung (project number 2024.133.1 to J.P.B.) and the European Research Council under the European Union’s Horizon Europe Framework Programme for Research and Innovation (grant agreement no. 101231434 — EICO-CODE to J.P.B.). J.E.-v.B. discloses funding by a Helmholtz Young Investigator grant from the Helmholtz Initiative and Networking Fund (VH-NG-1331) and grants from the Swiss National Science Foundation (310030_ 212312) and the DFG (490846870–TRR355/1 TPB09). M.C. discloses support by the DFG Priority Program SPP 2306 (CO 291/9-1, #461385412; CO 291/10-1, #461507177; CO 291/9-2; CO 291/10-2; and CO 291/14-1), the DFG CRC 353 (CO 291/11-1, #471011418), and the European Research Council under the European Union’s Horizon 2020 Research and Innovation Programme (grant agreement no. GA 884754). Open access funding provided by Eberhard Karls Universität Tübingen.

Author information

Authors and Affiliations

  1. Department of Experimental Immunology, Institute of Immunology, Eberhard Karls University of Tübingen, Tübingen, Germany

    Lukas Ramsauer, Anna-Marie Pedde, Anna Hirschberger & Jan P. Böttcher

  2. M3 Research Center, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany

    Lukas Ramsauer, Anna-Marie Pedde, Anna Hirschberger & Jan P. Böttcher

  3. Institute of Molecular Immunology, TUM University Hospital, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany

    María Parra Reyes, Nadine Nuschele, Felix Bayerl, Sebastian Lacher, Sainitin Donakonda, Martina Anton, Percy A. Knolle & Jan P. Böttcher

  4. Department of Internal Medicine II, TUM University Hospital, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany

    Kevin Schmid & Gabriela M. Wiedemann

  5. Center of Allergy and Environment, Technical University of Munich and Helmholtz Munich, Munich, Germany

    Benedikt Spitzlberger & Julia Esser-von Bieren

  6. Institute of Virology, School of Medicine and Health, Technical University of Munich (TUM) and Helmholtz Munich, Munich, Germany

    Daina Chakma & Gregor Ebert

  7. Department of Translational Genomics, Faculty of Medicine, University of Cologne and University Hospital Cologne, Cologne, Germany

    Christina M. Bebber & Silvia von Karstedt

  8. CECAD Cluster of Excellence, University of Cologne, Cologne, Germany

    Christina M. Bebber & Silvia von Karstedt

  9. Institute of Metabolism and Cell Death, Helmholtz Munich, Neuherberg, Germany

    Toshitaka Nakamura & Marcus Conrad

  10. Department of Biology, Stanford University, Stanford, CA, USA

    Scott J. Dixon

  11. Center for Molecular Medicine Cologne, Faculty of Medicine, University of Cologne and University Hospital Cologne, Cologne, Germany

    Silvia von Karstedt

  12. Hertie Institute for Clinical Brain Research, Tübingen, Germany

    Nicolas Snaidero

  13. Department of Immunobiology, University of Lausanne, Epalinges, Switzerland

    Julia Esser-von Bieren

  14. Translational Redox Biology, TUM Natural School of Sciences, Technical University of Munich, Garching, Germany

    Marcus Conrad

  15. Tohoku University Graduate School of Medicine, Sendai, Japan

    Marcus Conrad

  16. Cluster of Excellence iFIT (EXC 2180) ‘Image Guided and Functionally Instructed Tumor Therapies’, Eberhard Karls University of Tübingen, Tübingen, Germany

    Jan P. Böttcher

Authors

  1. Lukas Ramsauer
  2. Anna-Marie Pedde
  3. Anna Hirschberger
  4. María Parra Reyes
  5. Nadine Nuschele
  6. Felix Bayerl
  7. Sebastian Lacher
  8. Sainitin Donakonda
  9. Kevin Schmid
  10. Benedikt Spitzlberger
  11. Daina Chakma
  12. Martina Anton
  13. Christina M. Bebber
  14. Gabriela M. Wiedemann
  15. Toshitaka Nakamura
  16. Gregor Ebert
  17. Scott J. Dixon
  18. Percy A. Knolle
  19. Silvia von Karstedt
  20. Nicolas Snaidero
  21. Julia Esser-von Bieren
  22. Marcus Conrad
  23. Jan P. Böttcher

Contributions

L.R., M.C. and J.P.B. conceptualized the study. L.R., A.-M.P., A.H., M.P.R., N.N., F.B. and D.C. performed the investigation. L.R., A.-M.P., A.H., M.P.R., N.N., S.L., B.S., F.B. and S.D. conducted the formal analysis. L.R., A.-M.P., A.H., M.P.R., N.N., F.B., K.S., G.M.W., G.E., S.D., N.S., J.E.-v.B. and J.P.B. developed the methodology. M.A., C.M.B., T.N., P.A.K., S.J.D. and S.v.K. provided resources. J.P.B. supervised the study. L.R. and J.P.B. wrote the manuscript. All authors contributed to feedback and proofreading.

Corresponding author

Correspondence to Jan P. Böttcher.

Ethics declarations

Competing interests

M.C. holds patents for some of the compounds described in this study. J.P.B. and P.A.K. hold a patent related to the work in this article. All other authors declare no competing interests.

Peer review

Peer review information

Nature thanks Stefani Spranger, who co-reviewed with Vidit Bhandarkar and Fiona Chatterjee; and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data figures and tables

Extended Data Fig. 1 Ferroptosis induction by genetic ablation of Gpx4 or pharmacological inducers triggers PGE2 production in cancer cells.

a-d, Quantification of PGE2 production in cancer cells upon genetic ablation of Gpx4. Gpx4−/− BRAFV600E melanoma cells (a), Gpx4−/− LLC lung cancer cells (b) and Gpx4−/− MC38 colorectal cancer cells (c) were deprived of the lipid peroxidation inhibitor ferrostatin-1 (Fer-1) to induce ferroptosis and PGE2 production was measured 24 h later (n = 3 samples). d, Measurement of PGE2 production by CreERT2 Gpx4fl/fl small cell lung cancer (SCLC) cells after treatment with or without 4-hydroxy-tamoxifen (4-OHT) for 72 h (n = 3 samples). e,f, Measurement of PGE2 production in NRASG12D melanoma (e) or 4T1 breast cancer (f) cells treated with the ferroptosis inducers RSL3, ML210 or Erastin (n = 3 samples). g, PGE2 production by human HT-29 cells treated with RSL3 or Necrocide-1 (NC1) for 24 h. (n = 3 samples). h, Analysis of PGE2 production in MC38 cells treated with necroptosis-inducing combination of TNFα, LCL-161 and Emricasan for 24 h (n = 4 samples). Data in a-f are representative of two independent experiments. Centre of box plots in a-f indicate the mean with bounds showing the minimum and maximum values. Bar graphs in g indicate mean ± s.e.m. Data in h are depicted as box plots extending from the 25th to 75th percentiles with the median as the centre and the whiskers corresponding to the minimum and maximum values. P-values in a-d, h are from unpaired Student’s t-tests (two-sided), P-values in e-g are from one-way ANOVA with Tukey’s multiple-comparison test (two-sided). NS, not significant (P ≥ 0.05).

Source data

Extended Data Fig. 2 PGE2 production by ferroptotic cancer cells depends on lipid peroxidation and is observed across mouse and human cancer cell lines.

a,b, Measurement of PGE2 production (a) and cell viability (b) for indicated cancer cell lines treated with the ferroptosis inducer RSL3 with or without inhibition of lipid peroxidation by liproxstatin-1 (Lip-1), caspase inhibition (z-VAD-FMK) or RIPK1 inhibition (Nec-1S) for 24 h (n = 3 samples). c-e, Effect of RSL3-mediated ferroptosis induction on PGE2 production for indicated (c) mouse and (d) human cancer cells (MC38, 4T1, LLC, CT26, PancO2, NRASG12D, D4M.3 A, PDAC #10158, PDAC #53578, PDAC # 6075, PDAC #4888, Su86.86, PDAC #1, PDAC #2, PDAC #3, PDAC #4, A549, HT-29, n = 3 samples; BRAFV600E, n = 7 samples; SCLC #Rp181.5, n = 4 samples; SCLC #278.3, n = 2 samples). e, Plot showing the relative increase in PGE2 production induced by RSL3-mediated ferroptosis across mouse and human cancer cells from c and d (MC38, 4T1, LLC, CT26, PancO2, NRASG12D, D4M.3 A, PDAC #10158, PDAC #53578, PDAC # 6075, PDAC #4888, Su86.86, PDAC #1, PDAC #2, PDAC #3, PDAC #4, A549, HT-29, n = 3 samples; BRAFV600E, n = 7 samples; SCLC #Rp181.5, n = 4 samples; SCLC #278.3, n = 2 samples). Data in a-e are representative of two independent experiments. Centre of box plots in a,c,d indicate the mean with bounds showing the minimum and maximum values. Bar graphs in b,e indicate mean ± s.e.m. P-values in a,b are from one-way ANOVA with Tukey’s multiple-comparison test; P-values in c-e are from unpaired Student’s t-tests. NS, not significant (P ≥ 0.05).

Source data

Extended Data Fig. 3 Ferroptotic cancer cells impair cDC1 functions.

a, Quantification of CXCL9 production in cDC1s exposed to PGE2 (100 ng/ml) or conditioned medium (CM) from ferroptotic control BRAFV600E cells treated with the ferroptosis inducers RSL3 or ML210 for (n = 4 samples). b,c, cDC1s were treated with cancer cell CM as indicated, stimulated with poly I:C and analysed for IL-12 production by intracellular staining. b, Representative flow cytometry plots showing IL-12 expression. c, Quantification of IL-12+ cDC1s, based on b (n = 4 samples). d, Effect of PGE2 or CM from ferroptotic BRAFV600E cells on CXCL9 production in splenic cDC1s and cDC2s, measured after intracellular staining by flow cytometry (n = 6 samples). e, Effect of PGE2 or CM from ferroptotic BRAFV600E cells on chemokine and cytokine production by poly I:C-activated cDC1s, measured in the culture supernatant by bead-based flow cytometric analyses (n = 6 samples). f-h, Analysis of cDC1s by RNA-seq (n = 4). f, Venn diagram showing the overlap between core functional cDC1 genes inhibited by factors derived from ferroptotic cancer cells (Ferroptosis CM) and synthetic PGE2. g, Correlation analysis of core functional cDC1 genes regulated by PGE2 and ferroptotic cancer cell CM. h, GSEA of pathways linked to cDC1 functions in cDC1s exposed to ferroptotic cancer cell CM. Data in a,c,d,e are pooled from two independent experiments. Data in a,c,d are depicted as box plots extending from the 25th to 75th percentiles with the median as the centre and the whiskers corresponding to the minimum and maximum values. Plots in b show data for one cDC1 culture representatitve of n = 4 cDC1 cultures analysed in two independent experiments. In h, the red line indicates the linear regression fit with the 95% confidence interval shaded in grey. P-values in a,c,d are from one-way ANOVA with Tukey’s multiple-comparison test. P-values in g are from two-sided Pearson correlation analysis. NS, not significant (P ≥ 0.05).

Source data

Extended Data Fig. 4 Blockade of Ca2+ influx prevents PGE2 production by ferroptotic cells.

a-d, Effect of ferroptosis on PGE2 production in Pfa1 cells. a, Measurement of PGE2 production after treatment with the ferroptosis inducers RSL3, ML210 or Erastin (n = 3). b, Quantification of Ptgs1, Ptgs2, Ptges1 and Ptges2 mRNA expression in Pfa1 cells treated with RSL3 for 8 h (n = 3). c, Representative confocal microscopy images showing COX2 protein expression 8 h after RSL3 treatment. Scale bar 10 µm. c, Quantification of COX2 expression based on d. (n = 34). e,f, Pfa1 cells were treated with the lipid peroxide inducer cumene-H2O2 and analysed for Ptgs2 over Hprt mRNA expression after 8 h (e) or PGE2 production after 24 h (f). g, Representative microscopy images showing Ca2+-influx as measured by Fluo-8-AM staining in indicated cancer cell lines treated with RSL3 for 8 h. Scale bar 30 µm. h, Quantification of Ca2+ influx, based on g (BRAFV600E DMSO control, n = 82; BRAFV600E RSL3, n = 112; NRASG12D DMSO control, n = 58; NRASG12D RSL3, n = 85; 4T1 DMSO control, n = 62; 4T1 RSL3, n = 71; MC38 DMSO control, n = 80; MC38 RSL3, n = 84; D4M.3 A DMSO control, n = 77; D4M.3 A RSL3, n = 61). i-l, Pfa1 cells were stimulated with the ferroptosis inducer RSL3 with or without the osmoprotectant polyethylene glycol 3350 (PEG) and analysed by confocal microscopy imaging 8 h later. i, Visualisation of intracellular Ca2+. Scale bar 10 µm. Dashed lines indicate cell borders. j, Quantification based on i (DMSO control, n = 26; RSL3, n = 41; PEG, n = 23; RSL3 + PEG, n = 24). k, Representative images showing lipid peroxide induction, as measured by BODIPY C11 staining. Scale bar 10 µm. l, Quantification based on k (DMSO control, n = 17; RSL3, n = 43; PEG, n = 38; RSL3 + PEG, n = 38). m, Representative images of microscopy analysis of Ca2+- (Fluo-8-AM) and small molecule (FITC-dextran)-influx in Pfa1 cells treated with RSL3 for 8 h. Scale bar 10 µm. n, Quantification of intracellular Ca2+ and FITC-dextran based on m . DMSO: Calcium (n = 12), 4kDa Dextran (n = 6), 70 kDa Dextran (n = 6); RSL3: Calcium (n = 11), 4kDa Dextran (n = 5), 70 kDa Dextran (n = 6). o, Representative images of microscopy analysis of Na+-influx (Sodium-Green) into Pfa1 cells treated with RSL3 for 8 h. Scale bar 10 µm. Dashed lines indicate cell borders. p, Quantification of intracellular Na+ based on o (n = 54). q, Quantification of Ptgs2 mRNA expression in Pfa1 cells, BRAFV600E melanoma and MC38 colorectal cancer cells after 2 h of treatment with the Ca2+ ionophore ionomycin (5 µM) (n = 3). r, PGE2 production by Pfa1 cells, BRAFV600E melanoma and MC38 colorectal cancer cells treated with the ionomycin (5 µM) for 6 h. (n = 3). s,t, Live cell microscopy-based single-cell tracing of Ca2+-influx (Fluo-8-AM) and loss of membrane integrity as marker for cell death induction (7-AAD) for RSL3-treated Pfa1 cells incubated without (s) or with (t) the calcium-chelator EGTA (RSL3, n = 9; RSL3 + EGTA, n = 10). Data in a,b,d-f,h,j,l,n,p-r, are representative for 2 independent experiments. Plots in c,g,i,k,m,o,s,t are representative of 3 independent experiments. Centre of box plots in a,b,e,f,q,r indicate the mean with bounds showing the minimum and maximum values. Data in n are depicted as box plots extending from the 25th to 75th percentiles with the median as the centre and the whiskers corresponding to the minimum and maximum values. Data in s and t are presented as mean values ± s.e.m. P-values in d-f,h,p,q,r, are from unpaired Student’s t-tests (two sided); P-values in a,b,j,l,n are from one-way ANOVA with Tukey’s multiple-comparison test (two sided). NS, not significant (P ≥ 0.05).

Source data

Extended Data Fig. 5 PGE2 production in ferroptotic cancer cells requires Ca2+-mediated activation of p38 MAPK signalling; p38 MAPK signalling and Ca2+ influx are dispensable for ferroptotic cancer cell death.

a, Quantification of cell death in Pfa1 cells treated with or without the ferroptosis inducer RSL3 in combination with EGTA, SB203580 or PEG 3350 (n = 3 samples). b, PGE2 production by RSL3-treated MC38 cancer cells treated or not with PEG or SB203580 (n = 3 samples). c-e, Measurement of PGE2 production in RSL3-treated BRAFV600E melanoma (c), NRASG12D melanoma (d) or 4T1 breast cancer cells (e) treated or not with the osmoprotectant PEG or p38 inhibitor SB203580 for 24 h (n = 3 samples). f-k, Representative western blot and quantification of p-p38 and total p38 protein in Pfa1 (f,g), BRAFV600E melanoma (h,i) and MC38 colorectal cancer cells (j,k) treated with RSL3 with or without Lip-1 for 8 h (n = 3 samples). l-n, PGE2 production by Pfa1 (l), BRAFV600E melanoma (m) and MC38 colorectal cancer cells (n) treated with RSL3 with or without Lip-1 for 8 h (n = 3 samples). o-r, Representative western blot and quantification of p-p38 and total p38 protein in BRAFV600E melanoma (o,p) and MC38 colorectal cancer cells (q,r) treated with RSL3 with or without PEG 3350 for 8 h (n = 3 samples). s-v, Measurement of cell viability in RSL3-treated BRAFV600E melanoma (s), NRASG12D melanoma (t), 4T1 breast cancer (u) or MC38 colorectal cancer (v) cells treated or not with the p38 inhibitor SB203580 for 24 h (n = 3 samples). w, Effect of p38α deficiency on PGE2 production by MC38 cancer cells treated or not with the ferroptosis inducer RSL3 for 24 h (n = 3 samples). x, Effect of p38α deficiency on PGE2 production by Pfa1 cells treated or not with the ferroptosis inducer RSL3 for 24 h (n = 3 samples). y, Measurement of cell viability for WT and p38α–/– MC38 colorectal cancer cells treated or not with the ferroptosis inducer RSL3 for 24 h (n = 3 samples). Data in a-e,g,i,k-n,p,r,s-y are representative for 2 independent experiments. Plots in f,h,j,o,q show data for 1 sample representative of n = 6 samples analysed in 2 independent experiments. Centre of box plots in b-e,g,i,k-n,p,r,w,x indicate the mean with bounds showing the minimum and maximum values. Bar graphs in a, s-v,y indicate the mean ± s.e.m. P-values are from one-way ANOVA with Tukey’s multiple-comparison test (two-sided). NS, not significant (P ≥ 0.05).

Source data

Extended Data Fig. 6 PGE2 produced by ferroptotic cancer cells promotes cDC1 dysfunction.

a, Measurement of cell viability for Ptgs1/2–/– BRAFV600E melanoma cells treated with the ferroptosis inducer RSL3 with or without inhibition of lipid peroxidation by liproxstatin-1 (Lip-1), caspase inhibition (z-VAD-FMK) or RIPK1 inhibition (Nec-1S) for 24 h (n = 3 samples). b, Quantification of lipid peroxidation, as measured by BODIPY C11 staining, in control and Ptgs1/2–/– BRAFV600E melanoma cells treated or not with RSL3 for 8 h (n = 4 samples). c, Quantification of PGE2 production by control and Ptgs1/2–/– BRAFV600E cells treated with RSL3 for 24 h (n = 3 samples). d,e, Effect of EP2/EP4-deficiency on ferroptotic cancer cell-induced cDC1 dysfunction. Analysis of production of CD8+ T cell co-stimulatory cytokine IL-12 in wildtype (WT) or ItgaxCrePtger2−/−Ptger4fl/fl cDC1s. d, Representative flow cytometry plots showing expression of IL-12 in cDC1s. e, Quantification of IL-12+ cDC1s based on d (WT, n = 6 samples; ItgaxCrePtger2−/−Ptger4fl/fl, n = 5 samples). f,g, cDC1s were incubated for 16 h with CM from PGE2-sufficient (control) or PGE2-deficient (Ptgs1/2−/−) ferroptotic BRAFV600E cancer cells, before stimulation with different innate immune stimuli, as indicated, for 4 h. f, Representative flow cytometry plots showing CXCL9 production in cDC1s after activation with indicated stimuli. g, Quantification of CXCL9+ cDC1s, based on f (n = 3 samples). h,i, cDC1s were incubated for 16 h with CM from indicated ferroptotic cancer cells that were cultured in presence or absence of the inhibitor of the key PGE2-producing enzyme COX2, celecoxib (CXB), before stimulation with poly I:C for 4 h. h, Representative flow cytometry plots showing CXCL9 production as marker for cDC1 function. i, Quantification of CXCL9+ cDC1s, based on h (n = 4 samples). Data in a-c, g, i are representative of two independent experiments. Plots in d, f, h show data for 1 sample representative of n = 6 samples (d,f) or n = 7 samples (h) analysed in 2 independent experiments. Data in e are pooled from two independent experiments. Bar graphs in a-c,e indicate mean ± s.e.m. P-values in a-c,e are from one-way ANOVA with Tukey’s multiple-comparison test. NS, not significant (P ≥ 0.05).

Source data

Extended Data Fig. 7 Ablation of PGE2-EP2/EP4 signalling permits cDC1s to mount CD8+ T cell responses against ferroptotic cancer cells.

a-e, Analysis of cDC1-dependent stimulation of anticancer CD8+ T cell responses after in vivo transplantation of PGE2-sufficient (control) or PGE2-deficient (Ptgs1/2−/−) ferroptotic BRAFV600E-OVA cells into wildtype or Clec9aCrePtger2−/−Ptger4fl/fl mice. a, Experimental design. b, Flow cytometry plots showing the expansion of OVA-specific CD45.1+ CD8+ OT-I T cells in the spleen at day 9 after ferroptotic cancer cell transplantation. c, Quantification of CD45.1+ CD8+ OT-I T cell numbers, based on b (wildtype, n = 7 mice; Clec9aCrePtger2−/−Ptger4fl/fl, n = 6 mice). d, As in b but for draining lymph nodes (dLNs). e, Quantification of CD45.1+ CD8+ OT-I T cell numbers, based on d (wildtype, n = 7; Clec9aCrePtger2−/−Ptger4fl/fl, n = 6). f, Analysis of OT-I T cell expansion in spleens and dLNs of cDC1-deficient Batf3−/− mice transplanted with ferroptotic control or Ptgs1/2−/− BRAFV600E-OVA cells (n = 6). Plots in b,d show data for 1 sample representative of n = 6 samples analysed in 2 independent experiments. Data in c,e and f are pooled from two independent experiments and are depicted as box plots extending from the 25th to 75th percentiles with the median as the centre and the whiskers corresponding to the minimum and maximum values. P-values in c,e,f are from one-way ANOVA with Tukey’s multiple-comparison test (two-sided). NS, not significant (P ≥ 0.05).

Source data

Extended Data Fig. 8 Gpx4−/− MC38 tumours exhibit ferroptosis and high COX pathway activity.

WT or Gpx4−/− MC38 cells were transplanted s.c. into wildtype mice. After 8 days, tumours were analysed for staining of the ferroptosis biomarker 4-HNE by immunohistochemistry (a,b) or COX2 protein expression by immunofluorescence confocal microscopy (c,d). a, Representative images of 4-HNE immunohistochemical staining. Scale bar 500 µm (overview), 50 µm (zoomed area). b, Quantification of 4-HNE+ tumour area, based on a (n = 3). c, Representative confocal images showing COX2 expression. Scale bar 500 µm (overview), 80 µm (zoomed area). d, Quantification of COX2+ tumour cells, based on c (n = 4). Plots in a and c show data for one sample representative of n = 3 samples (a) or n = 4 samples (c). In the Box plots in b, the centre indicates the mean with bound showing the minimum and maximum values. Data in d and are depicted as box plots extending from the 25th to 75th percentiles with the median as the centre and the whiskers corresponding to the minimum and maximum values. P-values are from unpaired t-tests (two sided). NS, not significant (P ≥ 0.05).

Source data

Extended Data Fig. 9 Preventing PGE2-EP2/EP4 signalling in cDC1s restores anticancer CD8+ T cell immunity and achieves elimination of ferroptotic tumours.

a, Individual tumour growth profiles of WT or Gpx4−/− MC38 cells transplanted into wildtype or Clec9aCrePtger2−/−Ptger4fl/fl mice. b, Tumour growth profiles of WT or Gpx4−/− MC38 cells transplanted into wildtype or Cd4CrePtger2−/−Ptger4fl/fl mice. (n = 6). c, Quantification of PGE2 production in (p38α sufficient) WT and p38α−/− Gpx4−/− MC38 colorectal cancer cells 24 h after ferroptosis induction by deprivation of the lipid peroxidation inhibitor ferrostatin-1 (Fer-1) (n = 3). d, Tumour growth profiles of WT or Gpx4−/− MC38 cells with or without additional p38α knockout (p38α−/−) transplanted into wildtype mice. (n = 8). e,f, Analyses of cDC1-CD8+ T cell interactions in WT or Gpx4–/– MC38 tumours by volumetric microscopy, 6 days after tumour transplantation into wildtype or Clec9aCrePtger2–/–Ptger4fl/fl mice. e, Representative confocal images (upper panels) and corresponding 3D-rendered visualizations (middle and lower panels) showing cDC1–CD8+ T cell clusters. The middle panels show the same overview regions with rendered cells, and the lower panels show a zoomed-in view of the indicated area with rendered cells. Dashed lines indicate tissue borders; white squares mark zoomed regions; yellow circles highlight cDC1–CD8+ T cell clusters. Scale bars 100 µm (overview) and 30 µm (zoomed area). f, Quantification of intratumoural cDC1-CD8+ TIL clusters, based on e (n = 4). Data in b,d are pooled from two independent experiments. Centre of box plots in c indicate the mean with bounds showing the minimum and maximum values. Plots in b,d indicate the mean value ± s.e.m. Plots in e show data for 1 sample representative of n = 4 samples analysed in 2 independent experiments. Data in f are depicted as box plots extending from the 25th to 75th percentiles with the median as the centre and the whiskers corresponding to the minimum and maximum values. P-values are from two-way analysis of variance (ANOVA) with Bonferroni’s correction for multiple testing (b,d) or one-way ANOVA with Tukey’s multiple-comparison test (two-sided) (c,f). NS, not significant (P ≥ 0.05).

Source data

Extended Data Fig. 10 Clec9aCrePtger2−/−Ptger4fl/fl mice exhibit enhanced anticancer CD8+ T cell responses; inhibition of COX-driven PGE2 production improves immune control of ferroptotic tumours.

a-c, WT or Gpx4−/− MC38 cells were transplanted s.c. into wildtype or Clec9aCrePtger2−/−Ptger4fl/fl mice and CD8+ TILs were analysed 8 days later by flow cytometry. a, Flow cytometric analysis of effector and stem-like T cell marker expression in TIM-3+ and TCF1+ CD8+ TILs from Gpx4−/− MC38 tumours in Clec9aCrePtger2−/−Ptger4fl/fl mice. b, Quantification of TCF1+CD8+ TILs (WT MC38 into wildtype, n=7; Gpx4−/− MC38 into wildtype, n = 8; WT MC38 into Clec9aCrePtger2−/−Ptger4fl/fl, n = 8; Gpx4−/− MC38 into Clec9aCrePtger2−/−Ptger4fl/fl, n = 8). c, Flow cytometric analysis of Ki-67 in TIM-3+CD8+ TILs. d-f, Analyses of CD8+ TILs at day 10 after transplantation of WT MC38 cells into wildtype mice or Gpx4−/− MC38 cells into wildtype or Clec9aCrePtger2−/−Ptger4fl/fl mice (n = 6). d, Quantification of CD8+ TILs. e, Analysis of GZMB-expressing TIM-3+CD8+ TILs. f, Analysis of Ki-67-expression in TIM-3+CD8+ TILs. g, Effect of CD8+ T cell depletion on Gpx4−/− MC38 tumour growth in wildtype (n = 12) or Clec9aCrePtger2−/−Ptger4fl/fl mice (n = 11). h, Quantification of CD8+ T cell-mediated tumour elimination, based on g. i, Individual tumour growth profiles of Gpx4−/− MC38 tumours with or without CD8+ T cell depletion in wildtype (n = 12) or Clec9aCrePtger2−/−Ptger4fl/fl mice (n = 11), based on g. j, (non-ferroptotic) WT or (ferroptotic) Gpx4−/− MC38 cells were transplantation s.c. into wildtype mice treated or not with CXB (30 mg/ml per day) and GZMB+ TIM-3+CD8+ TILs were analysed at day 8 (n = 5). k, Tumour growth profiles of (non-ferroptotic) WT or (ferroptotic) Gpx4−/− BRAFV600E melanoma cells transplanted into wildtype mice treated or not with CXB (30 mg/ml, daily). WT BRAFV600E, n = 9; Gpx4−/− BRAFV600E, n = 16; WT BRAFV600E + CXB, n = 9; Gpx4−/− BRAFV600E + CXB, n = 18). l, Wildtype mice were transplanted s.c. with BRAFV600E cells. From day 5 after tumour transplantation, mice were treated with CXB or IKE (40 mg/ml) as indicated, and the change in tumour size was analysed 14 days later (Untreated, n = 20; + IKE, n = 20; + CXB, n = 22; + IKE and CXB, n = 20). Data in b,d-l are pooled from two independent experiments. Plots in a,c show data for one tumour representative of n = 6 tumours analysed in two independent experiments. Data in b,d-f,j are depicted as box plots extending from the 25th to 75th percentiles with the median as the centre and the whiskers corresponding to the minimum and maximum values. Plots in g,k indicate the mean value ± s.e.m. P-values are from two-way analysis of variance (ANOVA) with Bonferroni’s correction for multiple testing (g,k), one-way ANOVA with Tukey’s multiple-comparison test (b,d-f,j), logrank (Mantel-Cox) test (h) or Brown-Forsythe and Welch ANOVA (l). NS, not significant (P ≥ 0.05).

Source data

Supplementary information

Supplementary Fig. 1 (download PDF )

Flow cytometry gating strategies. Flow cytometry plots showing the gating strategies for analysis of antigen-experienced (CD44+) tumour-infiltrating CD8+ T lymphocytes (TILs) (a), intratumoural cDC1s and cDC2s and (b) cDC1s and cDC2s in splenocytes pre-enriched by pan-DC magnetic bead isolation (c)

Reporting Summary (download PDF )

Supplementary Fig. 2 (download PDF )

Western blots for p-p38 MAPK signalling. Uncut western blots showing p-p38, total p38 protein expression and Hsp60 loading control. Red boxes indicate regions shown in the indicated figures. The full legend for the molecular weight marker used for western blotting is shown on the bottom right for reference

Supplementary Table 1 (download XLSX )

Ferroptotic cancer cell CM-mediated regulation of activation induced genes in cDC1s. Lists of genes regulated between poly I:C stimulated cDC1s pre-treated or not with ferroptotic cancer cell CM

Supplementary Table 2 (download XLSX )

Regulation of core activation-induced genes suppressed by ferroptotic cancer cell CM in WT and EP2/EP4-deficient cDC1s. Lists of normalised read counts and differential regulation of core activation induced genes suppressed by ferroptotic cancer cell CM in poly I:C-stimulated (EP2/EP4-proficient) WT cDC1s. Data are shown for WT and EP2/EP4-deficient cDC1s treated with or without poly I:C or CM from ferroptotic cancer cells

Supplementary Table 3 (download XLSX )

Gene sets used for gene set enrichment analysis (GSEA). Gene lists for cell migration, antigen uptake and cross-presentation, cytokine signalling and PGE2-impaired functional cDC1 genes used for GSEA of RNA-seq data from cDC1

Peer Review file (download PDF )

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ramsauer, L., Pedde, AM., Hirschberger, A. et al. Ferroptosis in cancer cells triggers PGE2 production for tumour immune escape. Nature (2026). https://doi.org/10.1038/s41586-026-11333-6

Download citation

  • Received: 29 October 2025

  • Accepted: 19 October 2026

  • Published: 18 November 2026

  • Version of record: 18 November 2026

  • DOI: https://doi.org/10.1038/s41586-026-11333-6

来源:Nature 综合主刊 · nature.com